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ABSTRACT 
 
Human influenza is a contagious respiratory disease resulting in substantial 
morbidity and mortality worldwide. With the recent cases of avian influenza infections  
in humans and the heightened concern for an influenza pandemic arising from these 
infections, it is essential to understand host responses that would confer protective 
immunity to influenza.  The cell-mediated immune responses to influenza virus play an 
important role during influenza infection.   
To analyze the specificity and diversity of memory T-cell responses, we 
performed a genome-wide screening of T cell epitopes to influenza A virus in healthy 
adult donors.  We identified a total of 83 peptides, 54 of them novel, to which specific T 
cells were detectable in interferon-(IFN-γ) enzyme-linked immunosorbent spot assays 
(ELISPOT) using peripheral blood mononuclear cells (PBMCs) from four healthy adult 
donors. We found that among 11 influenza viral proteins, hemagglutinin (HA) and matrix 
protein 1 (M1) had more T-cell epitopes than other viral proteins. The donors were not 
previously exposed to H5N1 subtype, but we detected H5 HA T cell responses in two of 
the four donors.  To confirm that HA is a major target of T cell responses we also 
analyzed H1 and H3 HA-specific T-cell responses using PBMC of additional 30 adult 
donors. Fifteen out of thirty donors gave a positive response to H3 HA peptides, whereas 
five of thirty donors gave a positive response to H1 HA peptides.  
Because we detected T cell responses to the H5 HA peptides in donors without 
prior exposure to H5N1 subtype, we asked if cross-reactive T cells to H5 HA peptides 
vii 
 
can be attributed to a prior exposure to H2N2 subtype, the closest HA to the H5 based on 
their phylogeny.  We compared younger donors who have no prior exposure to H2N2 
subtype and older donors who were likely to be exposed to H2N2 subtype, and both 
groups responded H2N2 peptides at similar level, suggesting that memory T cells cross-
reactive to H5 HA peptides can be generated by prior exposure to the H1N1 and H3N2 
subtypes, and the exposure to H2N2 subtype is not necessary. We subsequently identified 
a CD4+ T cell epitope that lies in the fusion peptide of the HA.  This epitope is well 
conserved in all 16 subtypes of HA of influenza A and the HA of the influenza B virus.  
A CD4+ T cell line specific to this epitope recognizes target cells infected with various 
influenza A viruses including seasonal H1N1 and H3N2, a reassortant H2N1, the 2009 
pandemic H1N1, H5N1 and influenza B virus in cytotoxicity assays and intracellular 
cytokine staining assays.  Individuals who have the HLA-DRB1*09 allele have ex vivo 
IFN-γ responses to this epitope peptide in ELISPOT. Although natural infection or 
standard vaccination may not induce strong T and B cell responses to this very conserved 
epitope in the  fusion peptide, it may be possible to develop a vaccination strategy to 
induce these CD4+ T cells which are cross-reactive to both influenza A and B viruses. 
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CHAPTER I 
INTRODUCTION 
 
Influenza is a contagious respiratory illness in humans ranging from mild to severe, 
and at times can lead to death.  It causes significant morbidity and mortality worldwide. 
There are, on average, more than 200,000 hospitalizations  associated with influenza 
illness each year (220).  In a survey of influenza-related mortality in the United States 
between 1976 and 2007, the number of deaths can range from 3,000 to 48, 000 (32).  The 
elderly and children younger than five years are more susceptible to influenza, as shown 
by the rates of influenza-associated primary respiratory and circulatory hospitalizations 
(220).  Influenza A viruses (IAV) are the major type of influenza virus that causes disease 
in humans, and while influenza B viruses (IBV) can also infect humans, they do so to a 
less severe extent (151).  These viruses cause acute illness and do not result into 
persistent infections in humans, but they are maintained in circulation in the population 
and are detectable all year round by direct person-to-person spread during acute 
infections (240).    
 
A. The nature of influenza viruses 
The influenza viruses are segmented negative stranded RNA viruses that belong to the 
family Orthomyxoviridae. There are three genera or types of influenza virus - 
influenzavirus A, influenzavirus B, and influenzavirus C - based on the antigenic 
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differences in the matrix protein (M) and the nucleoprotein (NP) (124).  Influenza A, B, 
and C viruses have a common evolutionary precursor (151).  Based on comparative 
sequencing studies using the hemagglutinin (HA) protein component, it is estimated the 
IAV HA gene diverged from the IBV HA gene  more recently than from the 
hemagglutinin-esterase-fusion (HEF) gene, the HA equivalent in influenza C virus (212).  
The divergences between the different subtypes of IAV HA genes are estimated to have 
occurred from several thousand to several hundred years based  on the rate of amino acid 
substitution in HAs isolated from aquatic birds (212).   Influenza B and C viruses seem to 
be near or at an evolutionary equilibrium in humans, while the genes of type A viruses 
were introduced into the human population less than 150 years ago and were most likely 
derived from birds (240). 
Influenza A viruses are classified into subtypes, which are determined by differences 
in the nucleic acid sequences of the hemagglutinin (HA) and the neuraminidase (NA) 
viral proteins (151).  At present, there are 17 known HA subtypes and nine NA subtypes 
(67, 222, 231).  Except for the most recently identified H17 HA which was isolated from 
a bat species (222),  all 16 HAs and nine NAs have been isolated and identified from wild 
aquatic birds, which are considered to be the natural reservoir for IAV (240).  IAV can 
also naturally infect swine, horses, seals, whales and mink (151).  Virus strains are named 
accordingly and they include the host of origin (if the host organism is not human), 
geographic location of the first isolation, strain number and year of isolation, with the 
particular subtype in parenthesis (4).  Thus, an IAV that was the 8th virus isolated from a 
person in Puerto Rico in 1934 was given the name A/PuertoRico/8/1934 (H1N1), while 
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an IAV isolated from a duck in Vietnam is named A/Dk/Vietnam/568/2005 (H5N1).  
Influenza B viruses are not classified into subtypes, although strains are usually identified 
by the lineage that they belong to.  IBV strains that have been described in the last 
century or so started out as a homogenous group that eventually diverged into two 
distinct lineages – the B/Victoria and the B/Yamagata lineages (179).  IBV strains are 
also named following the guidelines for IAV, except that there is no subtype designation 
(4). 
   
i. Virus structure and protein  components 
The IAV particles are usually spherical in shape with a diameter of about 100 nm, 
although filamentous particles that can be as large as 300 nm have been observed in 
certain conditions (151).  The virus structure is quite complex and is depicted in Figure 
1.1.  It is characterized by distinctive spikes comprising of the HA and NA proteins that 
are jutting out of the viral lipid envelope, which is derived from the host cell membrane 
where the virus has previously replicated (151).  The matrix 2 protein (M2) also 
comprises the viral envelope (125) and serves as an ion-channel, playing an important 
role in the release of the viral genome into the cytoplasm (37, 157).  Underlying the viral 
envelope is a shell of matrix 1 protein (M1) (69) that encapsulates the ribonucleoprotein 
(RNP) complex.  The RNP complex is made up of an RNA segment in close association 
with the nucleoprotein (NP) and the viral polymerase proteins PB1, PB2 and PA 
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Figure 1.1.  A schematic representation of the structure of influenza A virus.  
Reprinted with permission from Nelson and Holmes Nature Reviews Genetics 2007: 8, 
196–205. (License No. 2845511024333). 
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(113, 146).    IAV and IBV are made up of the eight RNA segments, while influenza C 
viruses only have seven segments.  These RNA segments have a negative sense, are 
single-stranded, and comprise the influenza viral genome (151).  The eight RNA 
segments and the corresponding viral protein they encode for are listed in Table 1.1.   
More recently, an alternative open reading frame in the PB1 gene was identified 
encoding for a novel influenza protein called PB1-F2 (36).  It localizes in the 
mitochondria and promotes apoptosis in cells that are exposed to synthetic PB1-F2 (36).  
A third major polypeptide from the PB1 segment called N40 has also been recently 
described which is derived from a differential AUG codon usage (237).  Not all influenza 
isolates express the PB1-F2 and N40 proteins.  The non-structural proteins 1 and 2 (NS1 
and NS2) are only found in infected cells and are not part of the virion.     
Influenza B viruses are very similar to IAV by electron microscopy (181).  The 
IAV and IBV may have the same number of RNA segments, the IBV genome only 
encodes for ten proteins, as the PB1-F2 protein or the N40  has not yet been identified in 
IBV (151).   Table 1.1 highlights the main differences between IAV and IBV in terms of 
their genome and sequence similarities between related proteins.   
 
 
 
 
6 
 
Table 1.1. Comparison of IAVa and IBVb viral proteins.d   
Segment Name aa length in IAV aa length in IBV aa similarity (%) 
1 PB2 759 770 37 
2 PB1 757 750 61 
3 PA 716 726 36 
4 HA 566 585 28 
5 NP 498 566 37 
6 NA 469 466 30 
7 M1 252 248 31 
7c M2/BM2 97 109 26 
8 NS1 230 281 very low 
8c NS2/NEP 121 122 24 
 
a Prototype strain used is A/Sydney/5/1997 (H3N2). 
b Prototype strain used is B/Florida/02/2006. 
c The alternate ORF of this protein is encoded by a spliced mRNA within the vRNA 
segment. 
d Table is modified from (98). 
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ii. Influenza A virus life cycle 
 The influenza virus infects the host cell through the binding of the viral HA to 
sialic-acid containing receptors on the cell membrane (233, 235).  The human influenza 
A viruses preferentially bind to sialic acid residues attached to galactose by an α-2,6 
linkage, while the avian influenza A viruses prefer the α-2,3 linkage (43) .   These α-2,6 
sialic acid receptors are preferentially expressed on human airway epithelial cells (70).  
The virus is internalized via the endocytic pathway, where the low pH in the endosomes 
allows for the acidification of the virus interior by pumping H+ through the M2 ion 
channels leading to the dissociation of M1 from the RNP (92).  The low pH also causes a 
structural change in the HA, promoting the fusion of the viral membrane with the 
endosomal membrane (51, 198) and releasing the dissociated RNPs into the cytoplasm. 
The RNPs, which contain the genetic material needed for the replication of the 
virus, are then transported into the nucleus via interactions with NP (161), where the viral 
RNA segments are transcribed into mRNA through the aid of the viral polymerase PB1 
(95).  The polymerase PB2 cleaves 5’-capped fragments from newly synthesized host cell 
mRNA that will serve as primers for viral mRNA synthesis, a phenomenon called cap-
snatching (22, 117, 159).  A poly-A tail is also added to the newly transcribed viral 
mRNA (160).  This mRNA is transported back into the cytoplasm for protein translation 
(193), where newly synthesized HA, NA and M2 proteins are shuttled to the cell 
membrane through the ER and the Golgi apparatus (144, 201) while the polymerase 
proteins PB1, PB2, PA and NP are brought back to the nucleus to form new RNP 
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complexes (201).  On the other hand, NS1 sequesters host mRNA in the nucleus and 
prevents pre-mRNA splicing and polyadenylation, providing an ample supply of cap 
structures for viral transcription while inhibiting host gene expression (166).   
 The PA is required for both transcription of viral proteins and replication of the 
viral genome (87, 143).  M1 and NS2 mediate the nuclear export of the newly formed 
RNP (131, 147).   M1 associates with the RNP and both are brought , by yet unknown 
mechanisms, to the apical side of the plasma membrane where the HA, NA and M2 
proteins are assembled, eventually packaging the M1 and RNP complex into new virus 
particles (144).  The virus particles are released from the cell membrane by the action of 
NA, where it cleaves off the sialic acid from the virion and the cellular glycoproteins 
(144).   
 
iii.  The Influenza Hemagglutinin 
The HA is one of two surface viral glycoproteins, making up about 25% of the total 
viral protein (142).  As described briefly above, HA is indispensable in the viral life cycle 
because it is necessary for binding the viral receptor on target cells and mediating the 
fusion of viral and cellular membranes (48, 199).  The active form of HA consists of 
trimer of identical subunits that are anchored in the viral membrane due to the 
hydrophobic transmembrane sequences in the C-terminal region of the protein (199).  
The two subunits that consists a monomer of HA, HA1 and HA2, are linked by a 
disulfide bond, and they are products of the enzymatic cleavage of the precursor protein 
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HA0.    This cleavage step occurs extracellularly by a trypsin-like protease that is 
restricted in the respiratory tract epithelia (73) and renders the virus infectious.  For some 
of the HAs of the H5 and H7 subtypes, polybasic sequences are inserted at the cleavage 
site, allowing these HAs to be cleaved intracellularly by furin-like enzymes and is 
thought to be related to the widespread systemic and virulent infections by these subtypes 
in birds (199).   
The homology among the different IAV HAs is variable.  H2 and H5 HA are the most 
closely related HA (80% homology), while H3 and H1 HA are the most divergent (25% 
homology) (7, 67) .  Most of the homology is located in the HA2 subunit, including the 
highly conserved fusion peptide sequence (48).  In fact,  analysis of evolutionarily 
conserved sequences in the different influenza A viral components reveal that the 
FGAIAGFIE sequence of the fusion peptide is the only region in the HA protein that is 
98-100% conserved in influenza viral strains of the different human and avian influenza 
subtypes that circulated between 1997 to 2006 (91).   Comparisons between the HAs of 
A/Puerto Rico/8/34 (A/PR/8) and B/Lee/40 also show significant conservation in the first 
12 amino acids of the fusion peptide sequence (118). This conservancy is probably due to 
the critical role of this domain in triggering fusion and destabilizing target membranes 
during the fusion process (48).   
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B. Influenza genetics and epidemiology 
Influenza viruses undergo constant antigenic variation to escape the host immune 
response.  This characteristic largely defines the epidemiology of the viruses. These 
variations are brought about by two distinct mechanisms that are influenced by the nature 
and design of the viral genome as well as by selective immune pressure.  Antigenic drift 
is a consequence of the error-prone RNA polymerase-dependent replication, which 
introduces point mutations leading to gradual antigenic changes in the HA or NA proteins 
(231).  Some drift variants can amplify and survive because of escape from neutralizing 
antibodies (240).  These gradual changes may also affect host species range and influence 
disease severity.  Drift variants can occasionally cause epidemics and can typically 
prevail for two to five years before it is replaced by another variant (240).  The HA is the 
major antigenic component of influenza and all neutralizing antibodies that confer 
sterilizing immunity are targeted to the HA.  Five antigenic domains have been defined 
by studying the structure of H3 HA, all of which are located in the HA ectodomain (240).  
Antibodies to NA have also been detected and they help to prevent cell-to-cell spread of 
the virus, but do not neutralize it (112).  Antigenic drift in the NA has also been reported 
(240). 
A second mechanism in which viral diversity is achieved is through antigenic shift.  
A shift is brought about by the reassortment of the viral RNA segments from one virus 
subtype with the genes of a different subtype.  This typically occurs between human and 
avian viruses, where in vivo reassortment has been seen among human and avian strains 
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as well as between human and avian strains (240).  Antigenic shift can also occur by 
direct transmission of an avian or swine virus into the human population (29).   This 
“mixing” of genes can generate viral proteins that are now immunologically distinct from 
previously circulating strains.  When a virus subtype resulting from an antigenic shift is 
able to successfully establish transmission within a species, in particular in humans,  
higher infection rates  and increased morbidity and mortality are observed, which can 
ultimately lead to a pandemic (240).   
 
C. Influenza pandemics: a historical perspective 
 Influenza pandemics occur when there are major changes brought about by 
antigen shift, introducing a novel influenza virus to which human population has not been 
previously exposed.  In theory, novel influenza viruses that are encountered by our 
immune system have the capacity to initiate an influenza pandemic if they accrue enough 
mutations that would allow them to infect human cells and be efficiently transmitted from 
one person to the next (241).  In the last 400 years, about 31 pandemics have been 
recorded (127), four of which occurred in the recent century (Figure 1.2).  The mortality 
impact of these pandemics can range from devastating to mild (127), as exemplified by 
the 1918 “Spanish” influenza pandemic and the 2009 swine-origin H1N1 pandemic 
respectively.   
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Figure 1.2.  Influenza through the years.  We are constantly exposed to influenza 
antigens in our lifetime.  Influenza viruses have been circulating in the human population 
in the last hundred years or so.  As of late, only three IAV subtypes have successfully 
established human-to-human transmission: H1N1 emerged in 1918 and was replaced by 
H2N2 in 1957.  H3N2 replaced H2N2 in 1968 and has been circulating since then, amidst 
constant antigen drift.  The H1N1 subtype re-emerged in 1977 and is believed to be 
related to the H1N1 of the 1940’s.  It co-circulated with H3N2 until the emergence of a 
new H1N1 subtype in 2009, which has effectively replaced the previous H1N1.  In the 
past fifteen years, some avian influenza subtypes (e.g. H5N1, H7N7) have directly 
infected humans, although transmission within the human population has not been 
established.  IBV co-circulates with IAV.  In the 1940’s, influenza vaccination was 
introduced and since then has been available annually. 
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A usual hallmark of pandemic influenza is the distinct shift in the mortality rate, where 
younger individuals are more affected.  During the three pandemics of the 20th century, a 
significant proportion of influenza-related mortality included individuals less than 65 
years old (196). 
 The first influenza pandemic of the 20th century came in three distinct waves in 
1918 and spread throughout Europe, Asia and North America (14, 214).  Called Spanish 
flu, it is deemed to be the deadliest pandemic in history, where an estimated 50 million 
people died from influenza, more than the number of people killed during World War I, 
which was happening simultaneously (106).  The young and healthy (between 15 to 35 
years old) were disproportionally affected and 99% of the deaths were in people younger 
than 65 years old. Taubenberger and colleagues were able to recover the genomic RNA 
of the 1918 virus from archived formalin-fixed lung autopsy material (215) and from 
frozen, unfixed tissue from an influenza victim who was buried in permafrost in 
November 1918 (170) and performed initial genetic characterization of the 1918 flu 
virus, identifying it as subtype H1N1virus that may have arose from an avian-like 
predecessor that was able to adapt to humans (170).   
 The succeeding pandemics that came after 1918 were milder and had fewer 
excess deaths.  These happened in 1957 (Asian flu, H2N2), 1968 (Hong Kong flu, H3N2) 
and 1977 (Russian flu, H1N1) (96) (Figure 1.2).  The 1957 pandemic was caused by an 
H2N2 subtype, effectively replacing the H1N1 that had been in circulation.  This new 
subtype had acquired novel HA, NA and PB1 genes from an avian H2N2 virus (185, 
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240).  H2N2 circulated for about ten years and has not been detected in the human 
population since 1968.  The H3N2 subtype is also thought to have originated from China 
and caused an epidemic in Hong Kong  in 1968, eventually spreading to other countries 
(41).  The HA of the previously circulating H2N2 was replaced with an avian-derived H3 
HA gene segment, retaining the N2 NA gene segment (185, 232). The PB1 gene segment 
was also replaced, and is speculated to be derived from an avian source as well (110).  In 
1977, an H1N1 subtype caused epidemics in Russia and China that quickly spread 
globally and primarily affected younger people with relatively mild presentation (111).  It 
has been determined that the 1977 H1N1 is closely related to H1N1 strains that were 
isolated between 1947 and 1957 (186).  The 1977 H1N1 subtype did not replace the 
H3N2 in circulation; instead it co-circulated with H3N2 and maintained its presence in 
seasonal epidemics (251), alongside IBV (Figure 1.2).    
 More recently, a novel H1N1 subtype emerged in 2009 (6).  The 2009 H1N1 
caused large epidemics in Mexico and the United States that eventually spread across the 
globe (2, 33, 99).  The 2009 H1N1 was eventually determined to be of swine origin, 
where majority of the gene segments are closely related to common swine influenza 
viruses (1, 227).  This 2009 H1N1 subtype effectively replaced the seasonal H1N1 strains 
that circulated previously.  
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D. Avian influenza in humans 
The zoonosis of avian influenza is usually only limited to birds and these subtypes 
have caused major outbreaks in livestock chicken populations intermittently, leading to 
significant economic and social impact (reviewed in (31)).    However, the Centers for 
Disease Control and Prevention (CDC) has documented avian influenza of the subtypes 
H5, H7, and H9 to have infected humans (http://www.cdc.gov/flu/avian/gen-info/avian-
flu-humans.htm).  Highly pathogenic strains of influenza A have only been identified and 
restricted to the H5 and H7 subtypes (reviewed in (8)).   
In the last two decades, there were documented bird-to-human transmissions of 
H5N1 in 1997 (3)  and H7N7 in 2003 (66), causing outbreaks in Hong Kong and the 
Netherlands respectively.  In 2005, avian H5N1 infections in humans were documented 
in Southeast Asia, which eventually spread out to the rest of the continent (218).  This 
avian influenza subtype was determined to be of the highly pathogenic strain and brought 
about elevated concern with regards to its ability to be transmitted from one person to 
another.  Since then, global surveillance of avian influenza species have become a norm 
because of the possibility that these viruses may acquire mutations that would allow for 
human-to-human transmission that can potentially result in a pandemic.  As of December 
30, 2011, there have been 574 recorded cases of human avian influenza infections 
globally, 337 of which turned out to be fatal, a case fatality rate (CFR) of 58.7% 
(http://www.wpro.who.int/NR/rdonlyres/B44D349B-3DF1-4573-8286-
8F81C5FC9B02/0/AIWeekly313WPRO30Dec2011.pdf).  From the same report, 23.2% 
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of the cases occurred in individuals between the age range of 20-29 and the highest CFR 
was seen in the 10-19 age range (73%).  However, these numbers do not include those 
who may have been infected by H5N1 but were asymptomatic or did not present febrile 
or respiratory illness.  The stringent criteria that the World Health Organization (WHO) 
utilize to confirm an H5N1 infection prompted a recent meta-analysis of data from 
different studies that determined the seroprevalence of avian H5N1 infection in humans 
(230).   They found that  about 1 to 2% of the 12,500 study participants from 20 studies 
have sero-evidence for prior H5N1 infection (230). 
 
E. Influenza vaccination 
One of the more effective ways to reduce disease burden by a viral infection is 
through vaccination.  The goal of any vaccination regimen is to produce a long-lasting, 
(and if possible, a lifetime) protective immune memory.  However, due to the nature of 
influenza viruses, this has become an elusive goal.  Influenza viruses are constantly 
undergoing antigenic drifts and can also undergo occasional shifts. Additionally, there are 
two subtypes of IAV and a strain of IBV that have been are co-circulating every flu 
season since 1977.  Thus, the current vaccination strategy of influenza requires accurate 
prediction of the influenza strains that may circulate in the coming flu season and this 
relies on viral surveillance of circulating strains causing human disease in the past season 
worldwide (65).  The WHO recommends the composition of the seasonal influenza 
vaccine based on this surveillance data.  Although vaccination is not mandatory, most 
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countries have special recommendations and guidelines that are in place for vaccination 
of high-risk individuals for influenza (149).  According to the CDC, this group includes 
children under five years old and adults over 65 years old, pregnant women, those with 
medical conditions that may leave them immunocompromised, and health care workers 
(http://www.cdc.gov/flu/keyfacts.htm).    
In the United States, there are two types of licensed influenza vaccines being 
administered.  The more common one is the trivalent, inactivated vaccine (TIV) 
composed of H1N1 and H3N2 seasonal flu strains and an IBV strain.  Since the 
emergence of the novel H1N1 in 2009, the TIV composition for the 2011-2012 influenza 
season replaced the seasonal H1N1 with the 2009 H1N1.   TIV is introduced 
intramuscularly and given to individuals 6 months and older (CDC recommendations).  
They are commercially available and are regulated by the amount of HA (15ug per flu 
strain).  Alternatively, a live attenuated influenza vaccine (LAIV) is also available and is 
administered intranasally to individuals age 2 to 49 years old (CDC recommendations).  
In Europe, both formulations are available, as well as adjuvanted influenza vaccines 
(149).  Both the LAIV and the TIV can induce HA-specific antibody responses (60), 
which are determined by the hemagglutination-inhibition (HAI) antibody titers.   
The level of serum anti-HA antibodies has been used extensively as a correlate of 
protection and is indicative of vaccine efficacy (47).  Susceptibility to infection is 
inversely correlated with the anti-HA titers, usually determined by HAI, wherein a post-
vaccination titer of 1:40 indicates the level of antibody that is able to protect 50% of the 
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population  (163).  With recent advances in the field of viral immunology, there is a need 
to include other immune correlates of protection to evaluate vaccine efficacies.  In elderly 
populations, serum antibody levels may be limited as a measure of vaccine efficacy, 
while T cell responses correlated with protection (135).  There are also other antibodies 
generated to other components of the influenza virus, as well as other immune 
mechanisms, as discussed below, that may also serve as correlates of protection. 
 
F. The innate immune response to influenza 
The innate immune system serves as our first line of defense against an invading 
pathogen.  It is characterized by a non-specific response to a pathogen that can be readily 
mobilized upon infection.  On a cellular level, innate immunity is comprised of 
intracellular signaling cascades that trigger the production of cytokines that contribute to 
modulating and containing the infection.   These signaling cascades are initiated by the 
recognition of pathogen-associated molecular patterns (PAMPs) by pattern recognition 
receptors (PRRs).  Among these PRRs are the membrane-associated toll-like receptors 
(TLRs), which can recognize a variety of PAMPs, including viral RNA.  TLR-3 
recognizes double-stranded RNA, while TLR-7 recognizes single stranded RNA in the 
endosomal compartment (54, 85). The influenza viral life cycle allows for both mRNA 
species to trigger the innate immune response via these TLRs.  Influenza is also 
recognized by a cytosolic sensor of PAMPs called retinoic acid inducible gene – I (RIG-
I) (109).   Recognition of these influenza components by the PRRs and cytosolic sensors 
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leads to the induction of the type I interferon (IFN) pathway, a known potent antiviral 
mechanism (reviewed in (206)) that triggers a global antiviral state by the production of 
IFN-inducible effectors such as PKR, OAS and MxA (86).  The antiviral effects of type I 
IFN activation in influenza is antagonized by the NS1 protein, where a deletion of this 
gene in a reverse genetic system increased interferon induction and the virus generated 
following NS1 deletion were attenuated (72).  A third player in the innate immune 
recognition of influenza includes the intracellular NOD-like receptors (NLRs).  These 
NLRs have been shown to activate the inflammasome, a molecular platform involving 
several protein complexes that can activate caspase 1, an important enzyme that cleaves 
precursor forms of inflammatory cytokines such as interleukin (IL)-1 (140).  More 
recently, activation of the inflammasome by NLR recognition of influenza can influence 
the outcome of the subsequent adaptive immune response (97). 
 
G. The adaptive immune response to influenza 
The adaptive immune response plays an important role in protecting the host and 
eliminating pathogen.  It is characterized by high degree of specificity to distinct portions 
of the pathogen and the ability to establish memory to that pathogen.  This allows for a 
more rapid response to repeated exposures of the same pathogen. There are two arms to 
this response – the humoral, antibody-mediated response and the cellular T cell-mediated 
response.  Both arms of the adaptive immune response are involved during influenza 
infection (Fig. 1.3).  
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Figure 1.3.  Humoral and cellular immunity induced by influenza virus 
infection. (1) Influenza virus binds to the receptor on the host cell and entry the cell by 
receptor-mediated endocytosis. (2) The endosomal acidification permits fusion of the 
host and viral membranes by altering the conformation of hemagglutinin. (3) Upon the 
fusion, viral RNP complexes are released into the cytoplasm and (4) transported to the 
nucleus, where the viral RNAs (vRNA) are transcribed into messenger RNAs (mRNA) 
and replicated by the viral RNA-dependent RNA polymerase complex into 
complementary RNA (cRNA). (5) mRNA are exported to the cytoplasm for translation of 
structural proteins. (6) Synthesis of envelope proteins takes place on ribosomes of 
endoplasmic reticulum. (7) The newly synthesized viral RNPs are exported from the 
nucleus to the assembly site at the apical plasma membrane, where (8) new virus particles 
are budding and release out of host cells. Influenza virus infection triggers innate (not 
shown) and adaptive immune response where the effector cells and molecules are 
involved in restriction of viral spread, as follows: The cellular immune response (right) is 
initiated after recognition of viral antigens presented via MHCI and MHC II molecules 
by antigen presenting cells (APC), which then leads to activation, proliferation and 
differentiation of antigen-specific CD8+ T or CD4+ cells. These cells gain effector cell 
function and either they help directly (Th1 or Th2 cell) to produce antibodies or, CTL 
effector cells recognize antigen peptides presented by MHCI on APC and kill the virus 
infected cells by exocytosis of cytolytic granules. The humoral immune response (left)is 
mediated by specific antibodies (e.g IgG, IgA) produced by antibody secreting plasma 
cells (ASC) which are the final stage of B cell development. This process is aided by 
CD4+ T helper and T cell-derived cytokines essential for the activation and differentiation 
of both B-cell responses and CD8+ T cell responses. (Stanekova and Vareckova. 2010. 
Virology Journal.  7:351.   Reprinted with permission under the terms of the Creative 
Commons Attribu tion License (http://creativecommons.org/licenses/by/2.0), which 
permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.) 
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i. Antibody-mediated responses to influenza 
The humoral response is contributed by B cells and the antibodies that they 
secrete.  These antibodies recognize distinct structural components of the intact viral 
proteins that are present on the surface of the virus particle or on virus-infected cells.  
Neutralizing antibodies are particularly important because they can provide sterilizing 
immunity.  They can directly bind to virus particles, preventing virus entry into host cells.  
The antibody isotype IgA is locally secreted in the respiratory epithelia in response to 
IAV infection and persists for at least three to five months post infection in mice (34).  
Virus-infected cells that are coated with IgG antibody are recognized and lysed by natural 
killer (NK) cells via antibody-dependent cell- mediated cytotoxicity (88).  These 
antibodies may also bind infected cells and lyse them by activating the complement 
system (167, 228).  It has been established that the levels of HA- and NA-specific 
antibodies in the serum correlate with protection from illness following natural (46) or 
experimental infection (38).   
 Antibodies to HA, NA, NP and M are produced during influenza infections in 
humans (163).  In both mice and men, antibodies to HA and NA correlate with resistance 
to infection, while antibodies to M1 and NP do not (240).  The neutralizing antibodies to 
influenza are directed to HA and antibodies to NA modify severity.  Passive transfer of 
anti-HA antibodies can resolve influenza infection in T and B cell deficient SCID mice 
(184).  Monoclonal antibodies to M2 were previously generated and characterized from 
in vitro cell lines (248) and passive transfer of these antibodies conferred protection in 
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mice by reducing the level of viral replication in the lungs (226).  However, protection by 
antibody becomes progressively less efficient through time.  There is a gradual decrease 
of IgG and IgA antibodies as well as antibody secreting cells specific to influenza within 
the first year after initial infection (107, 239). High mutation rates of HA and NA genes 
also result to altered antibody binding sites leading to virus escape from antibody 
recognition, as described above. 
 
ii. T cell-mediated immune responses to influenza 
The T cell-mediated immune response to viral infections is also widely studied 
because of its importance in controlling pathogens.  Unlike antibodies that recognize 
intact viral proteins, T cells recognize short peptide fragments presented by professional 
antigen presenting cells in the context of an MHC molecule through the T cell receptor 
(TCR).  This MHC restriction is influenced by the expression of either the CD8 or the 
CD4 co-receptor on the T cell surface (103).   
A detailed description of the functions of CD8+ and CD4+ T cells has been reviewed 
by Janeway (103, 104).  In summary, CD8+ T cells recognize peptide bound to MHC 
class I molecules which are expressed on virtually all cell types.  The MHC class I 
molecules typically present peptides that 8-10 amino acids in length and are derived from 
endogenously synthesized proteins, including viral proteins that are actively produced 
during infection.  On the other hand, CD4+ T cells recognize peptide bound to MHC class 
II molecules.  The expression of MHC class II is limited to professional antigen 
24 
 
presenting cells and B cells.  Structural differences in the peptide binding groove of MHC 
class I and MHC class II allow for longer peptides (between 12 to 17 amino acids in 
length)  to bind to MHC class II molecules.  In addition, MHC class II molecules present 
antigens derived extracellularly.  Peptide fragments generated from the uptake of 
exogenous antigen into the acidified endosomes are then loaded onto the MHC class II 
complexes.  The recognition of a particular TCR and co-receptor with its cognate 
peptide-MHC complex stimulates a cascade of signaling events in the T cells, leading to 
their proliferation and differentiation into effector T cells.  These effector T cells can 
either directly or indirectly promote the lysis of infected cells.  Following resolution of 
infection, the effector T cell populations are down-regulated and a memory T cell pool is 
established and maintained, with the potential to rapidly respond against subsequent viral 
exposures.   
Much of what is known about the cell-mediated immunity to influenza has been 
gleaned using mouse models.  The availability of reagents and genetically-modified 
mouse models has allowed for an extensive analysis of the T cell response to influenza, 
although influenza in mice does not necessarily replicate what is seen in natural infection 
in humans, birds and other vertebrate species (219).   Mice that lack B cells were more 
susceptible to a lethal challenge of influenza, but priming with sub-lethal doses of 
influenza promoted resistance to a subsequent lethal infection and adoptive transfer of 
influenza specific CD8+ and CD4+ T cells prior to lethal challenge conferred protection in 
mice (80).  These results suggest a contribution by both CD8+ and CD4+ T cells to 
immunity to IAV.   
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The CD8+ T cell response is characterized by its ability to rapidly proliferate during 
the initial phase of a viral infection and its cytotoxic capacity.  Influenza-specific CD8+ T 
cells can contribute to protective immunity based on studies done in CD8+ T cell-
deficient mice, where there is delayed viral clearance (18).  Early on, CD8+ cytotoxic T 
cells (CTL) have been shown in murine studies to limit influenza A virus replication and 
to protect against lethal influenza A virus challenge (119, 121, 130).  Passive transfer of 
NP-specific CD8+ CTL can also protect against a lethal influenza infection in mice  
(216).  They are also able to mediate clearance of virus in mice that were depleted of 
CD4+ T cells (56).  Several of these CTL responses are cross-reactive, recognizing 
conserved components of the viral proteins, thus allowing them to lyse target cells that 
are infected with different influenza subtypes (240).  Indeed, several of these influenza-
specific CTLs target the viral internal proteins NP, M1 and viral polymerases (15, 19, 20, 
78, 171, 223, 224, 247).  The CTL memory response to influenza has also been studied in 
humans.   CD8+ CTL were detected in the peripheral blood lymphocytes of infected or 
vaccinated individuals by day 6 until day 14 and undergo contraction by day 21 (59).  A 
live influenza infection in human volunteers demonstrated that CTL can clear virus as 
seen by the reduction in viral titers and recovery in donors that had a robust T cell 
responses (137).   
CD4+ T cells are not essential in providing protective immunity in mouse models 
of influenza infection when both CD8+ T cells and B cells are present (reviewed in (27)).   
Optimal humoral and cellular immunity to influenza require the activation of CD4+ T 
helper cells (reviewed in (27)).  Influenza specific CD4+ T cells can provide help to B 
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cells and cross-reactive CD8+ T cells during infection and they may also regulate early 
innate immune responses by indirectly upregulating inflammatory cytokines and 
chemokines during the early stage of infection (209).  Mice that lack CD4+ T cells had 
compromised CD8+ T cell memory response after influenza challenge, suggesting that   
CD4+ T cells play a role in maintaining the CD8+ T cell cytotoxic responses and the 
transition to memory phase (17).   
CD4+ T cells can also act as antiviral effectors themselves upon sequential 
infection of two different influenza subtypes (136).  This cytotoxic effector function is 
carried out by a perforin-mediated mechanism, mediating protection against a lethal 
influenza infection in mice and inducing higher levels of neutralizing antibody titers (26).  
Teijaro and colleagues have shown that  memory CD4+ T cells specific to the H1N1 
influenza virus provide a protective immune response in the lungs after a lethal challenge 
in mice by enhancing T cell recruitment to the lungs (217).  Moreover, B cell deficient 
mice with HA-specific or polyclonal memory CD4+ T cells were protected from 
influenza virus challenge in the presence of CD8-depleting antibodies, thus 
demonstrating an intrinsic effector function for influenza-specific CD4+ T cells (217).   
In humans, the role of CD4+ T cells is not fully understood.  A recent study 
performed challenge experiments where they inoculated healthy human volunteers 
intranasally with influenza virus to demonstrate the contribution of the CD4+ T cell 
response to protection (236).  The challenge virus given to these individuals was 
determined by the absence of neutralizing antibody titers to that particular IAV in the sera 
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prior to infection.  They found significant correlation between influenza-specific CD4+ T 
cell responses and disease protection, suggesting a role for memory CD4+ T cells in 
influenza infection in humans. 
 
iii. Identification of T cell epitopes to influenza 
 The identification of T cell epitopes is important for understanding and analyzing 
cell-mediated immune responses in general, and is relevant in our understanding of 
disease pathogenesis, monitoring disease progression and developing vaccines (5).  T cell 
epitopes to various viral pathogens have been identified, including influenza.  Defining 
the T cell epitopes to influenza will enable us to determine which responses are specific 
for a given virus strain or subtype or which ones are cross-reactive, among others (28).  
Bui and colleagues compiled all influenza T cell epitopes described in literature in 2007 
(28).  Although several T cell epitopes have been determined from human samples (76, 
101, 102), they are biased because they utilized the sequences of the A/Puerto Rico/8/34 
(H1N1) strain (A/PR/8), a prototype strain that was isolated more than 70 years ago and 
is not a circulating strain.  Moreover, only a few epitopes have been determined using 
current isolates of human pathogenic strains (~1.2%, on average, for a given strain) 
compared to A/PR/8 (~24%) or A/X-31 (H3N2), a reassortant virus with internal genes 
from A/PR/8 strain and external genes of the A/Hong Kong/68, which is the H3N2 
prototype strain (~32%) (28).   There are also limited epitopes determined for influenza 
strains of pandemic potential, including the avian influenza subtype H5N1 strains (102).   
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H. Cytokines produced during influenza infection 
Cytokines are secreted signaling protein molecules that are rapidly produced by a 
variety of cell types during an immune response.  In the course of an influenza infection, 
cytokines are secreted by both innate and adaptive immune cells. A subset of cytokines, 
called chemokines, is also produced.  These chemokines act as chemoattractants that 
bring cells of the immune system to the site of infection.  Human plasmacytoid and 
myeloid dendritic cells have been shown to produce distinct waves of chemokines that 
allows for a coordinated recruitment of immune effectors, including neutrophils, natural 
killer (NK) cells, cytotoxic T cells and effector memory T cells (158).  Cytokines 
involved during the course of an influenza infection include IL-1α/β, TNF-α/β, IL-6, IL-
8, IFN-α/γ and  MIP1-α/β (16).    
IFN- γ is a pleiotropic cytokine that is secreted mainly by T lymphocytes, including 
T-helper 1 CD4+ T cells and cytolytic CD8+ T cells, and by NK cells (reviewed in (13)).  
During viral infection, IFN- γ promotes an antiviral state by inducing the  synthesis of 
host proteins that are able to inhibit viral replication (reviewed in (154)).  It also 
contributes to enhanced antigen presentation by inducing the expression of MHC 
molecules on antigen presenting cells (64) and by augmenting peptide degradation during 
antigen processing in the proteasome (245).   In a heterologous secondary influenza 
infection, IFN- γ deficient mice have impaired ability to clear the challenge virus, even 
though they have similar number of T cells and antibody (HAI) titers to wild-type mice 
(25).  This indicates a protective role for IFN-γ during secondary influenza infection. 
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TNF-α is another pleiotropic cytokine that is produced mainly by macrophages, but 
can also be secreted by T lymphocytes.  Although TNF-α is associated with systemic 
inflammation that may lead to septic shock (reviewed in (225) ), it has been shown to 
mediate inflammatory responses to several autoimmune diseases (116), as well as 
microbial (53) and viral infections (93), including influenza .  An influenza-specific 
CD8+ cytotoxic lymphocyte line producing both TNF- α and IFN-γ was shown to lyse 
mediated by both cytokines during the course of influenza infection (120).  Another 
cytokine produced during influenza infection is MIP1-β.  It is a chemokine secreted 
mainly by monocytes, CD4+ T cells and NK cells, and preferentially recruits CD4+ and 
CD8+ T cells and promotes neutrophil infiltration (132).     The outcome of the immune 
response to infection can lead to either protection or immunopathology depending on the 
interplay, timing, magnitude and location of these cytokines.   
 
I. Heterosubtypic Immunity to Influenza 
Heterosubtypic immunity (HSI) is the immunity generated by a given IAV 
subtype or its antigens that protects against challenge with a virus of another IAV subtype 
(e.g. immunity to H1N1 protecting against an infection with H3N2) (81).   It is 
hypothesized that T cells are the major contributors to HSI, especially T cells that target 
the internal proteins of influenza (81).  Because the internal viral proteins are conserved, 
T cells generated against them are potentially cross-reactive, allowing them to participate 
in a more rapid response upon challenge, thus enhancing virus clearance and reducing 
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immunopathology (81).  However, pre-existing T cells to influenza cannot prevent 
infection (sterilizing immunity) as this is the function of neutralizing antibodies.  These 
antibodies are usually specific only to the strain that they were raised against, and 
because of the propensity of influenza to antigenic drift, antibodies generated to a 
previous influenza infection may not be efficient in neutralizing a future influenza 
infection.  However, antibodies should not be totally discounted for a possible 
contribution to HSI. Cross-reactive monoclonal antibodies directed to the stem region of 
the HA have been described and characterized recently (45, 57, 210).  These recent 
developments also point to the contribution of cross reactive antibodies to HSI.  
 
i. HSI in mice and other animal models 
HSI was first demonstrated by Shulman and Kilbourne wherein mice that were 
previously infected or immunized with an H1 subtype of influenza virus had partial 
immunity against challenge with an H2 subtype of influenza as seen by reduced 
pulmonary viral titers, reduced mortality and less severe lung lesions (188).  This partial 
protection is specific only to influenza A viruses, since infection with an influenza B 
virus strain did not provide the same protection.  It is now well-established that a mild 
influenza infection in animals can provide protection against a subsequent and more 
severe challenge with a heterosubtypic virus containing a different HA and NA (reviewed 
in (63)).  This protection due to HSI has also been demonstrated in other vertebrate 
animals.  In ferrets, HSI was shown by a decrease in viral titers after a heterosubtypic 
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challenge and the immunity generated to the initial IAV infection lasted for 18 months 
(246).  Chickens that were primed with H9N2 survived a lethal challenge with H5N1 and 
this protection was mediated by T cells (191).   HSI also mediated protection to a 
different IAV subtype in pigs (90, 174) and cotton rats (207), reducing viral titers and 
modulating pathology in infected tissues.  Thus, HSI can contribute to decreased severity 
of a subsequent influenza infection by controlling viral titers and promoting viral 
clearance, diminished shedding and transmission. 
 
ii. HSI in humans 
 HSI has not been directly tested or demonstrated in humans and proves to be 
controversial (63).  Ideally, one would have to find an influenza sero-negative individual 
or know the history of influenza exposure to perform challenge experiments.  However, 
this is really hard to come by in human studies.  In theory, one could study HSI in 
pediatric cohorts, although there are confounding differences in the influenza 
susceptibility between adults and children (63).    The majority of what is known about 
HSI in humans has been gleaned from epidemiological evidence, usually relating 
incidence rates of one IAV subtype to previous exposure to a different subtype, either 
through natural infection or vaccination.  Interestingly, the occurrence of several 
pandemic events provided an avenue to study HSI in the context of two different IAV 
subtypes circulating in nature.  During the onset of the 1957 pandemic, a cohort of 
factory workers in the former USSR were surveyed to determine if a previous infection 
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with the H1N1 subtype that circulated the previous year would affect their susceptibility 
to the emerging H2N2 subtype (200).  They found that workers who were less likely to 
get sick with H2N2 had prior exposure to H1N1.   A similar observation was seen in a 
retrospective analysis of the Cleveland Clinic Family Study in the 1950s.  Adults who 
caught the flu in the prior year did not get sick or had relatively fewer symptoms when 
the H2N2 IAV emerged (61).  In both these studies, there is an indirect indication that 
although there were no neutralizing antibodies to H2N2 present in these individuals, they 
were partially protected against H2N2 via HIS generated from previous encounters with a 
different IAV subtype (61).  It is also thought that immunity to H2N2 may have provided 
protection during the onset of the 1968 pandemic, when H3N2 emerged, because these 
two subtypes share a common neuraminidase that may contain shared antigens that can 
contribute to cross-protection  (187).  
 
J. Thesis Objectives 
 The overall goal of this thesis is to characterize the breadth and depth of the 
influenza A specific CD8+ and CD4+ T cell responses in humans that are induced by 
natural infection and vaccination.  We hypothesize that a subset of the memory T cells 
generated from a previous encounter with influenza is cross-reactive and that these 
T cell responses may contribute to HSI to influenza with viruses of a different 
subtype. 
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This thesis is presented in two parts:  
CHAPTER III:  Genome-wide screening of human T-cell epitopes to influenza A 
viruses  
Question:  
 What are the targets of the human T cell response to influenza? 
 Are there cross-reactive T cell responses to specific viral components? 
 
Approach:  
 ELISPOT screening of human PBMC using peptides spanning all of the 
influenza viral proteins. 
 Generating peptide-specific T lines to further characterize the functionality 
and phenotype of these T cells. 
 
CHAPTER IV: A human CD4+ T cell epitope in the influenza hemagglutinin is 
cross-reactive to influenza A subtypes and to influenza B virus 
Question:  
 Are there cross-reactive T cells specific to the influenza HA? 
 Can we detect H2 HA-specific memory T cell responses in individuals who 
were previously exposed to H2N2? 
 Are these H2 HA-specific responses cross-reactive to H5 HA? 
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Approach: 
 ELISPOT screening using H2 HA peptides and comparing the profile of the IFN-
γ responses in two groups: older donors who have previously encountered the 
H2N2 and younger donors who are naïve to H2N2. 
 Characterization of HA specific responses by generating specific T cell lines. 
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CHAPTER II 
MATERIALS AND METHODS 
 
A. Influenza peptides and recombinant proteins 
Peptides encompassing the entire sequence of all influenza viral proteins were 
obtained from the National Institutes of Health (NIH) Biodefense and Emerging 
Infections Research Resources Repository (BEI Resources; Table 2.1).  They are 17 
amino acids in length with overlapping 11 to 12 amino acids. The peptide length was a 
debated compromise in an effort to detect most CD4+ and CD8+ T-cell epitopes at a 
reasonable cost. The amino acid sequences of these peptides were based on vaccine 
strains of influenza A viruses (H1N1 and H3N2 or an antigenically indistinguishable 
strain from the vaccine strain when the amino acid sequences of the proteins were not 
available for the vaccine strain) and recent isolates of influenza virus A (H5N1), as 
indicated in Table 2.1.   Because of the considerable difference between avian and human 
N1 NA amino acid sequences, peptide sets for both neuraminidases were synthesized. 
Polymerase B1-F2 peptides of both strains were also synthesized because of differences 
between the H1N1 and H3N2 strains.  Peptides covering the pre-hemagglutinin protein 
(pre-HA) of influenza B/Nanchang/12/1998 were also synthesized.  Control peptides for 
known major histocompatibility complex (MHC) class I and II epitopes of influenza A 
viruses were also provided by BEI Resources. Peptides spanning the HA of 
A/Japan/305/1957 (H2N2) were designed to correspond to BEI Resources’ H5 HA 
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peptides and synthesized by AnaSpec, Inc. (San Jose, CA).  A vaccinia virus B5R peptide 
(B5R5-19) was used as a negative control and was also obtained from AnaSpec, Inc.  All 
the peptides were reconstituted by dissolving in 100% dimethyl sulfoxide at a stock 
concentration of 10 mg/ml.   
The CEF peptide pool was obtained through the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, the National Institute of Allergy and Infectious 
Diseases (NIAID), NIH, and was used as a positive peptide pool control. This peptide 
pool contains MHC class I-restricted human T-cell epitope peptides of cytomegalovirus, 
Epstein–Barr virus, and influenza A virus (49).   
Recombinant HA proteins of A/Singapore/1/1957 (H2N2) and A/Canada/RV444/04 
(H7N3) were obtained from BEI Resources.  Recombinant HA proteins from A/New 
Caledonia/20/1999 (H1N1), A/Wisconsin/67/2005 (H3N2) and A/Vietnam 1203/2004 
(H5N1) were obtained from Protein Biosciences (Meriden, CT; H1, H3 and H5).  A 
recombinant vaccinia virus B5R protein was used as an irrelevant protein control and was 
provided by BEI Resources.
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B. Influenza viruses and other viruses 
For live virus infections, the following influenza virus strains were used: A/New 
Caledonia/20/1999 (H1N1), A/Wisconsin/67/2005 (H3N2), X-27 (reassortant of 
A/Rockefeller Institute/5/57 (HA) x A/NWS/34 (NA), subtype is H2N1), A/Hong 
Kong/483/1997 (H5N1), A/California /7/2009 NYMC (H1N1) and 
B/Malaysia/2506/2004.  The H1N1 and H3N2 seasonal virus strains and the influenza B 
virus were a gift from Dr. Michel DeWilde and Dr. Robert Ryall of Sanofi Pasteur.  The 
H5N1 strain was provided by Dr. Nancy Cox from the World Health Organization 
Influenza Reference Laboratory at the Centers for Disease Control and Prevention (CDC) 
and the reassortant H2N1 strain was obtained from BEI resources.  The 2009 pandemic 
H1N1 strain was provided by Dr. Alexander Klimov of the CDC.  The vaccinia virus WR 
strain was used as an unrelated virus control and was provided by Bob Marshall from the 
University of Massachusetts Medical School.   
All experiments using the live H5N1 strain were performed by John Cruz in  a 
biosafety level 3 laboratory of University of Massachusetts Medical School according to 
enhanced BSL3 guidelines (Federal Register / Vol. 74, No. 182 / Tuesday, September 22, 
2009 / Notices). 
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C. Human PBMCs used in this study 
Blood samples were obtained from healthy adult volunteers and their peripheral blood 
mononuclear cells (PBMCs) were purified by density gradient centrifugation using 
Ficoll–Hypaque (Sigma).  DNA from either PBMC or autologous B lymphoblastoid cell 
lines (BLCLs) were extracted for HLA typing using the Puregene DNA purification kit 
(Gentra Systems, Minneapolis, MN).  The HLA Class II typing for most of these donors 
was performed by either the HLA Typing Laboratory at the University of Massachusetts 
Medical Center or by the HLA Core Facility of the Center for Infectious Diseases and 
Vaccine Research (now part of the Division of Infectious Diseases and Immunology) at 
the University of Massachusetts Medical School. 
The four donor PBMCs we used for our genome-wide screening of T cell epitopes in 
Chapter III were chosen based on either the availability of PBMCs for large-scale 
screening and/or their reactivity to the influenza peptides in the CEF peptide pool in 
enzyme linked immunosorbent spot (ELISPOT) assays that had been previously 
performed by Kim West in our laboratory.  Donors 1, 3, and 4 received the influenza 
vaccine almost every year.  Donor 2 never received any influenza vaccine. None of the 
four donors had a history of laboratory-confirmed influenza infection.  Additional 
screening of the H1 and the H3 HA peptides was performed using PBMCs from 30 
healthy hospital workers.  These donors were recruited for a clinical study that was 
previously described elsewhere (40).  The Day 0 bleed was used for the screening.  For 
screening of B/HA peptides, additional donor PBMCs were collected from healthy 
volunteers through the weekly blood draw in our laboratory.   
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For the screening of H2 HA peptide pools described in Chapter IV, donors were 
classified into two age groups based on their birth year and relative to their exposure to 
the H2N2 subtype that circulated from 1957 to 1968.  Older donor PBMCs (born on or 
before 1957) were originally obtained for a long-term vaccinia virus clinical study.  
These were comprised of hospital workers who did not report any febrile illness during 
blood draw. The younger donor PBMCs (born after 1968) were collected from healthy 
volunteers through the weekly blood draw in our laboratory.  Additional donors were 
sought to further characterize a cross-reactive CD4+ T cell peptide epitope that we 
identified in this study.  We chose donors who had the HLA-DRB1*09 allele.   PBMCs 
of these donors were previously collected for other studies in our laboratory and extra 
vials from these studies were used for the experiments described below. 
 
D. IFN-γ ELISPOT assay 
ELISPOT assays were performed as previously described (101).  Briefly, 
cryopreserved PBMCs (2–2.5 x 106 cells per well) were seeded onto polyvinylidene 
difluoride membrane 96-well plates (Millipore, Bedford,MA) precoated with 5µg/ml 
anti-IFN-γ monoclonal antibody (clone D1K; Mabtech, Cincinnati, OH) in the presence 
or absence of peptide or peptide pools.  Phytohemagglutinin (Sigma–Aldrich, St. 
Louis,MO;1:100),CEF peptide pool, and/or virus were used as positive controls. After 
18–24 hours of incubation, cells were removed by washing with phosphate-buffered 
saline plus 0.05% Tween 20. Secondary biotinylated anti-IFN-γ monoclonal antibody 
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(clone 7-B6-1; Mabtech) was added at 2 µg/ml and the plates were incubated for two 
hours at room temperature. Plates were washed again and IFN-γ was detected with 
avidin–peroxidase (3420-2H, Mabtech) and substrate kit (NovaRed, Vector Laboratories, 
Burlingame, CA). The frequency of IFN-γ-producing cells was determined by using the 
ImmunoSpot S4 Pro Analyzer and the ImmunoSpot Academic V.4 Software (Cellular 
Technologies Ltd., Shaker Heights, OH).  Experiments were usually performed in 
triplicate wells, with some repeat experiments done in duplicate wells. 
 
E. Peptide pool design 
For our genome-wide T cell epitope screening, we made peptide pools that contained 
15 non-overlapping peptides and made two sets of peptide pools to facilitate the peptide 
screening. The first set of peptide pools (Table 2.2) contains all peptides of the surface 
glycoproteins of H1, H3, and H5 HA and avian N1 (aN1) and human N1 (hN1) and N2 
NA. This set of peptide pools consists of 33 pools: pools 1–6 contain H1 HA peptides, 
pools 7–12 contain H3 HA peptides, pools 13–18 contain H5 HA peptides, pools 19–23 
contain hN1NApeptides, pool 24–28 contains aN1NA peptides, and pool 29–33 contains 
N2 NA peptides. The second set of peptide pools (Table 2.3) consists of 38 pools and 
included all peptides of the internal viral proteins: NP and nonstructural protein 1 (NS1; 
pool 1–8), M1 and nonstructural protein 2 (NS2; pool 9–12), polymerase A (PA) and 
matrix protein 2 (M2; pool 13–21), and polymerase B1 (PB1) and polymerase B2 (PB2; 
pool 22–38). Three additional peptide pools were also made (Table 2.2 Pool 34-36). 
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These contained PB1-F2 peptides and H5 HA peptides representative of regions of amino 
acid sequence diversity among different strains of H5N1 viruses. 
 In later ELISPOT screening experiments using H2 and B HA peptides, we 
designed non-overlapping peptide pools containing 9 or 10 peptides per pool at a stock 
concentration of 1.1 or 1 mg/ml respectively (Table 2.4).  
 
F. Depletion of CD4+ or CD8+ expressing cells from PBMCs 
CD4+ or CD8+ expressing cell populations were depleted from PBMCs by negative 
selection using anti-CD4 or anti-CD8 antibody-coated magnetic beads from the MACS 
purification system (Miltenyi Biotec, Bergisch Gladbach, Germany) and processed 
according to the manufacturer’s protocol. Depleted PBMCs were used in ELISPOT to 
determine the cell population producing IFN-γ.   
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Table 2.2. Peptide Pool Design: Set 1 – Hemagglutinins, Neuraminidases and PB1-
F2 
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Table 2.3. Peptide Pool Design: Set 2 – Influenza Internal Proteins 
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Table 2.4. Peptide pool design – H2 HAs and B HA 
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G. Generation of bulk culture cell lines 
To generate peptide-specific bulk culture lines, PBMCs (3 to 5 x 106 cells) were 
washed and resuspended in 2 ml of AIM/V-10% FBS supplemented with 1:100 sodium 
pyruvate (Gibco) and 1:1000 2-mercaptoethanol (Gibco). The corresponding influenza 
peptide was added at a final concentration of 10 µg/ml. Human recombinant interleukin 
(rhIL)-7 (Peprotech, Inc., Rockyhill, NJ) was also added to the culture (5 ng/ml) and 
incubated at 37  C. On day 3, human recombinant interleukin (rhIL)-2 (BD Discovery 
Labware, Bedford, MA; 25–50 U/ml) was applied, and the medium was replenished with 
AIM/V-10% FBS and rhIL-2 every 3 to 4 days. Bulk culture 51Cr release assays were 
performed between days 10 and 13 of culture. The cultures were restimulated once with 
autologous PBMCs on day 14 to reduce nonspecific background lysis and to generate 
enough cells for the assays.  To establish influenza A-specific T cell clones, a limiting 
dilution assay was performed as previously described (101). Briefly, PBMCs that had 
been stimulated in bulk culture for 14 days were plated at a concentration of 1, 3, 10, or 
30 cells per well in 96-well round-bottom microtiter plates in 50 µl of AIM-V medium 
containing 10% FBS, 25 U IL-2, a 1:1,000 dilution of anti-CD3 monoclonal antibody 
12F6 (gift from Dr. Johnson Wong), and 1 x 105 gamma-irradiated (3500 rads) allogeneic 
PBMCs/well. On day 7, 50 µl of fresh AIM-V medium with FBS and IL-2 was added, 
and on day 14, fresh medium with 1 x 105 gamma-irradiated allogeneic PBMCs/well and 
a 1:1,000 dilution of the anti-CD3 12F6 were added. The cells were assayed for cytolytic 
activity using 51Cr release assays between days 21 and 28. Cells from wells with 
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influenza A peptide-specific cytolytic activity (specific killing of 15% and above at a 
peptide concentration of 10 µg/ml) were expanded to 48-well plates.  
 
H. Preparation of antigen presenting cells (APCs) for 51Cr release assays and 
intracellular cytokine staining (ICS) 
For virus-infected targets, autologous B lymphoblastoid cell lines (BLCL) were 
established from donor PBMC by culture with Epstein–Barr virus in 24-well plates as 
previously described (82). BLCL target cells were infected with either of the following 
egg-adapted virus strains: A/New Caledonia/20/1999 IVR-66 or A/Wisconsin/67/2005X-
161B.  These virus strains were a gift from Dr. Michel DeWilde and Dr. Robert Ryall of 
Sanofi Pasteur. The optimal concentrations of the two strains were determined by John 
Cruz in preliminary experiments (unpublished results).  For infections using recombinant 
vaccinia virus expressing influenza HA, BLCLs were infected at an MOI of 1.   Infected 
cells were initially incubated for one hour in 300 ul PBS with 0.1% Bovine Serum 
Albumin (BSA) at 37oC.  RPMI-10 was added to bring the volume up to 1mL and the 
cells were incubated for up to 18 hours at 37ºC. Virus-infected target cells were then 
radiolabeled for use in 51Cr-release assays or used as APCs in ICS.  
Peptide-pulsed targets were prepared using autologous BLCLs that were either 
radiolabeled for one hour in CTL assays or used directly in ICS assays. Peptide is added 
to the cells at a final concentration of 10 µg/ml per peptide, unless indicated otherwise. 
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I. Cytotoxic T cell assay by 51Cr release 
Cytotoxicity was measured as described previously (101).  T-cell lines or bulk culture 
effector cells were added to 1.5x103 51Cr-labeled target cells at various effector to target 
(E:T) ratios.  Wells that had target BLCLs and media were used to determine the 
background (spontaneous) 51Cr release, while wells that had target BLCLs and detergent 
(10% name of detergent) were used to determine the maximum 51Cr release.  After 
incubation for 4–6 hours at 37ºC, supernatants were harvested (Skatron Instruments, 
Sterling, VA), and % specific immune lysis was calculated as [(experimental release - 
spontaneous release)/(maximum release - spontaneous release)] x 100. The % 
spontaneous lysis is given by the (spontaneous release/maximum release) x 100 and was 
<30% in all assays.  All conditions were performed in triplicate wells. Unpulsed target 
cells were used as a negative control.  
J. Surface and intracellular cytokine staining 
Bulk culture lines or T cell lines derived from limiting dilution assays were used as 
effector cells in ICS.  They were washed and resuspended at 5x105 cells in RPMI 1640 
medium supplemented with 10% FBS (RPMI 10). Autologous BLCLs were used as 
APCs at an E:T ratio of 10 and were added to the effector cells.  These were incubated 
for 1 hour at 37 C in a 5% CO2 incubator, followed by an additional five hours in the 
presence of Golgi plug (BD Biosciences, San Jose, CA). The cells were then washed with 
FACS buffer (2% FBS and 0.1% sodium azide in phosphate-buffered saline) and stained 
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using the Live/Dead aqua fixable dead cell stain kit (Invitrogen, Eugene, OR) to identify 
live and dead cells. Cells were then stained for surface markers such as CD3 (clone SK7, 
APC-Cy7; BD Biosciences, San Jose, CA) , CD8 (clone SK1, PerCP-Cy5.5 or clone 
RPA-T8, FITC; BD Biosciences, San Jose, CA), CD19 (clone SJ25C1, PE-Cy7; BD 
Biosciences, San Jose, CA) and/or CD56 (clone B159, PE-Cy7; BD Biosciences, San 
Jose, CA) and/or CD14 (clone M5E2, PE-Cy7; BD Biosciences, San Jose, CA), and CD4 
(clone OKT4, Pacific Blue; eBiosciences, San Diego, CA or clone RPA-T4, APC; BD 
Biosciences, San Jose, CA) for 30 minutes at 4oC. After washing with FACS buffer, the 
cells were fixed and permeabilized with Cytofix/Cytoperm (BD Biosciences, San Jose, 
CA) and stained for the intracellular cytokine IFN-γ (clone 4S.B3, PE or clone B27, 
Alexa Fluor 700; BD Biosciences, San Jose, CA) or tumor necrosis factor (TNF) -α 
(clone Mab11, APC; BD Biosciences, San Jose, CA) for 30 minutes at 4ºC. Cells were 
then washed with Permwash buffer (BD Biosciences, San Jose, CA) and resuspended in 
1X BD Stabilizing Fixative (BD Biosciences, San Jose, CA) for flow cytometric analysis. 
Multiparameter flow cytometric analyses were performed using the BD FACSAria flow 
cytometer. The number of events collected per experiment varied from 150,000 to 
300,000. List-mode data files were analyzed using FlowJo (Version 6.3 or 7.2, TreeStar 
6, Inc., Ashland, CA).  
 
K. Peptide binding assay 
A fluorescence polarization assay was used to determine the binding affinities of HA 
peptides containing the fusion peptide sequence to the HLA-DR1 molecule. The reagents 
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used for the assay were provided by Dr. Lawrence Stern and Liusong Yin from the 
University of Massachusetts Medical School.  The HA306–318 peptide probe (Ac-
PRFVKQNTLRLAT) was synthesized (21st Century Biochemicals, Marlboro, MA) and 
labeled with Alexa-488-tetrafluorophenyl ester (Invitrogen, Eugene, Oregon).  Soluble 
recombinant HLA-DR1was prepared as previously described (68).   Peptide-free HLA-
DR1 (100 nM) was mixed together with the Alexa-488-HA peptide probe (25nM) and 
varying concentrations of unlabeled competitor peptide (from 0.08 to 20 nM).  The 
mixtures were done in triplicate wells for each competitor peptide concentration in a 96-
well format and incubated for three days at 37 C in binding buffer (pH 5.5) containing 
protease inhibitors and 0.5 mg/ml octylglucoside.   Fluorescence was detected using the 
Alexa488-FP-DISS-one measurement protocol of the PerkinElmer 2030 Explorer 
multilabel plate reader.  IC50 values were obtained by fitting a binding curve of the plots 
of percent dissociation of peptide probe versus the logarithmic value of the concentration 
of competitor peptide using GraphPad Prism Version 5.04. 
L. Statistical analysis 
Statistical analysis of the ELISPOT responses of PBMC to peptide pools was done 
using GraphPad Prism Version 5.04.  One-way analysis of variance (one-way ANOVA) 
was performed to determine variations among the means of the different peptide pool 
responses.  An unpaired student’s t-test was performed comparing the mean of media 
only wells against a specific peptide pool response.  P values of ≤0.01 were considered 
significant.   
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CHAPTER III 
GENOME-WIDE SCREENING OF HUMAN T CELL EPITOPES TO 
INFLUENZA A VIRUSES 
 
Characterization of epitope specific T cell responses is relevant in understanding the 
immune response to influenza infection and vaccination.  Previous efforts to characterize 
the T cell response to influenza by our group (101) and others (76) were limited by 
focusing only on the conserved viral proteins or utilizing viral protein sequences derived 
from the A/PR/8 strain.  Other groups also focus on a particular influenza viral protein 
such as HA or M1 (50, 243), or determine influenza-specific T cell epitopes restricted to 
a particular HLA allele (242, 244).  Therefore, we sought to determine the baseline T cell 
memory responses to influenza by performing a genome-wide screening of T cell 
epitopes using synthetic peptides covering all viral proteins whose sequences are based 
on more recent circulating strains of influenza, including the avian H5N1.  ELISPOT was 
used to quantitate the number of IFN-γ-producing cells in donor PBMCs that are specific 
for the influenza A viral proteins.  This method of screening for T-cell epitopes directed 
to viral proteins had been used with much success (9), in particular with vaccinia virus 
(148).   
 
A. Peptide Screening 
We first sought to determine the optimal conditions in establishing a standard 
approach to screening IFN- γ responses using ELISPOT.  We have several vials of 
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PBMC collected from Donor 1, thus preliminary experiments were performed using this 
donor’s PBMC.  Donor 1 is HLA-A*02:01 positive and  was previously shown by Kim 
West in our laboratory to have  T-cell responses specific to the influenza CD8+ T cell 
epitope M158-66 (unpublished data), which is considered an immunodominant epitope 
(138).  We initially determined the optimal peptide concentration to use in our ELISPOT 
screening to minimize false positives and negatives by using 17-mer peptides that contain 
known influenza T cell epitopes that Donor 1 is expected to respond to.  We were able to 
detect IFN-γ responses to the M1 peptide containing the immunodominant M158-66 at all 
peptide concentrations but the spot forming cells/106 (SFC/106) were increased 
significantly when the peptide concentration was 2 µg/ml (Fig. 3.1).  There is no apparent 
explanation as to why we see a significant difference in the SFC values for the M1 
peptide epitope, since the DMSO used to reconstitute the peptides is essentially diluted 
(<0.1% of final volume in well).  We also did not observe a peptide dose response for the 
M1 peptide epitope since there was no trend of decreasing SFC values as peptide 
concentration decreases.   However, for the M1 peptide epitope, we consistently saw 
higher SFC values at 2 µg/ml compared to higher peptide concentrations (data not 
shown).  IFN-γ responses were also optimal at a peptide concentration of 2 µg/ml for the 
other peptide epitopes tested, with higher concentrations of the peptide giving minimal 
SFC values (Fig. 3.1).   
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Figure 3.1. Determining the optimal peptide concentration for our ELISPOT 
screening.  Donor 1 PBMCs were used to determine the minimal peptide concentration 
that would give positive IFN-γ responses in ELISPOT.  17-mer peptides containing 
known influenza epitopes were assayed at various concentrations.  M1 Peptide 10 
contains the HLA-A*0201 epitope M158-66, PB1 Peptide 69 contains the HLA-A*0201 
epitope PB1413-421, and H3 HA Peptide 55 contains the HLA-DR1 epitope H3 HA322-333.  
H3 HA Peptide 46 is a candidate peptide that had IFN-γ responses in our initial 
experiment.  SFC values are representative of one experiment and error bars are given by 
the standard deviation of the mean of triplicate wells.  PHA stimulation was used as a 
positive control (mean = 2545 SFC/106).  
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We only had limited peptide amounts and donor PBMC to perform our screening, 
thus we decided not to use the matrix system of designing peptide pools.  Instead, we 
explored the possibility of maximizing the number of peptides we can use in a pool and 
taking advantage of the overlapping nature of the synthetic peptides.  The number of 
IFN-γ-producing cells did not differ significantly if we used five, 10, or 15 non-
overlapping peptides in a pool (Table 3.1).  The PBMC also responded to the CEF 
peptide pool, which contains HLA-A*02:01-restricted T cell epitopes to CMV, EBV and  
influenza (49), including the influenza epitope, M158-66.  However, we saw a significant 
decrease in the SFC/106 values if we used a peptide pool that included overlapping 
peptides to M158-66 (Table 3.1).  Based on our results, we established for our screening 
that 15 non-overlapping peptides in a pool at a concentration of 2 µg/ml per peptide 
would allow us to detect influenza-specific IFN-γ responses in ELISPOT using human 
PBMC.   
We also wanted to determine the cut-off SFC for a positive response.  There is no 
set standard to determine the cut-off number of spots in ELISPOT screening.  In most 
cases, the number of spots in unstimulated or negative wells (background spots) is used 
to determine the cut-off.  We arbitrarily determined the cut-off of a positive ELISPOT 
response at 20 SFC/106 based on the value given by the mean of the spot-forming cells 
(SFC) per 106 cells plus three standard deviations (SD) of the negative control wells in 
our donors (Table 3.2).  For donors that had higher background spots, we adjusted the 
cutoff value for a positive response accordingly (see Donor 3, Table 3.2).   In later 
analyses,   peptide pools that had SFC values close to the arbitrary 20 SFC/106 cut-off  
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Table 3.1.  ELISPOT results of optimization experiments for peptide screening. 
Stimulation aSFC/106 
Experiment 1 Experiment 2 
PHA 1810.7 ± 31.7 1741.3 ± 33.0 
CEF peptide pool 230.7 ± 1.5 226.7 ± 5.5 
Overlapping peptide pool  0.3 ± 0.6 0.3 ± 0.6 
Non-overlapping peptide pool   
5 peptide per pool 37.3 ± 3.5 33.3 ± 4.9 
10 peptides per pool 40.0 ± 6.1 30.7 ± 1.2 
b15 peptides per pool-A 38.7 ± 2.1 34.7 ± 0.6 
c15 peptides per pool-B 36.0 ± 1.0 32 ± 6.08 
 
a SFC/106 values are given by the mean of three wells for each experiment and the 
standard error of the mean was calculated for each value. 
 
b Pool includes M1 peptide 10 (containing M158-66) and peptides from H3 HA, NS1, NP, 
PB1 and M2. 
 
c Pool includes M1 peptide 10 (containing M158-66) and non-overlapping M1 peptides. 
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Table 3.2. Background spots of negative control wells for Donors 1, 2, 3, and 4. 
 
Experiment 
SFC/106 
Donor 1 Donor 2 Donor 3 Donor 4 
1 3.5 12.5 17.5 2 
2 3.5 5 16.5 1 
3 2 5 18.5 2.5 
4 2 3.5 32 1.5 
5 1.5 3 21.5 4.5 
6 2.5 4 24 13.5 
7 9 6.5 17.5  
8 8 6 16.5  
9 4.5 0.5 26  
10 8  25.5  
Mean 4.5 5.1 21.6 4.2 
S.D. 2.8 3.3 5.2 4.7 
Cut-Off (Mean 
+3*S.D) 
12.9 15 37.2 18.4 
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were considered positive if the p-value were determined by using an unpaired student’s t-
test  was < 0.01.   
 
B. The PBMCs of Donor 1 have broad IFN-γ response to peptide epitopes on 
several influenza A proteins 
We performed a genome-wide screening of influenza T cell epitopes in Donor 1 using 
peptide pools that cover the entire influenza viral proteins.  The PBMCs of donor 1 were 
broadly reactive to peptide pools from several influenza proteins, as indicated by the IFN-
γ responses to peptide pools containing HA peptides (Fig. 3.2A; pools 1, 7, 8, 10, 11, 13, 
14, 15, 17 and 18), NA peptides (Fig. 3.2A; pools 29, 30 and 33), NP peptides and NS1 
peptides (Fig. 3.2B; pools 2, 3, 4, 5, 6, and 8), M1 and NS2 peptides (Fig. 3.2B; pools 9, 
10, 11, and 12), PA peptides (Fig. 3.2B; pool 20), and PB1 and PB2 peptides (Fig. 3.2B; 
pools 22 and 37).  IFN-γ responses to individual peptides from positive pools containing 
H3 HA and NS2 and M1 peptides are illustrated in Fig. 3.2C and D, respectively.  In 
addition, donor 1 had positive responses to two pools containing PB1-F2 and H5 HA 
variant peptides (data not shown). We also detected several IFN-γ responses to H3 but 
only one pool tested positive for H1 HA. For the internal viral proteins, the majority of 
responses were seen in pools containing M1, NP, NS1, and NS2 peptides. The pool that 
contained the peptide with the HLA-A2-restricted M1 epitope M158-66 (Fig. 3.2B; pool 
10) had the highest SFC value among all the peptide pools.  The sum of the number of 
IFN-γ-producing cells responding to these positive peptides was 1108, which is 90.7% of  
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Figure 3.2.  IFN-γ response of Donor 1 PBMC to peptides from all influenza 
proteins. PBMC were first tested in ELISPOT against (A) Set 1 peptide pools (1–33), 
which include the hemagglutinin (H1 HA, H3 HA, and H5 HA) and neuraminidase (aN1 
NA, hN1 NA, and N2 NA) peptides and (B) Set 2 peptide pools (1–38), which include 
peptides spanning all viral internal proteins. Positive pools were deconvoluted to test 
individual peptides. An example of such screening is illustrated in C and D. ELISPOT 
assays were performed using (C) individual peptides in Set 1 peptide pool 7, 10, and 11 
consisting of H3 HA peptides and (D) NS2 and M1 peptides contained in Set 2 peptide 
pools 9 and 10.   PHA stimulation was used as a positive control and was consistently 
above 2,000 SFC/106 in all experiments. Peptide pools and individual peptides were 
tested in triplicate wells with 200,000 to 250,000 cells per well. The final concentration 
of peptide used in all experiments was 2 µg/ml per peptide. The dotted line indicates the 
cutoff SFC value of positive responses for this donor (20 SFC/106) that determines which 
pools will be deconvoluted.  Error bars indicate the standard deviation among triplicate 
wells and statistical significance was determined by using unpaired Student’s t test (* = 
p<0.01, ** = p<0.001 and *** = p<0.0001).   
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the number of IFN-γ-producing cells responding to live influenza virus stimulation (1221 
SFC/106 for H1N1 and 1219 SFC/106 for H3N2; Table 3.4).  
 
C. IFN-γ responses to influenza A proteins in three other healthy adults 
We selected three additional donors based on the availability of PBMCs for large-
scale screening and their previous reactivity to the influenza peptides in the CEF peptide 
pool in preliminary ELISPOT assays.  All three of these donors responded to peptides 
from several influenza A viral proteins as summarized in Figure 3.3. The PBMCs of 
Donor 2 exhibited less reactivity to influenza peptides, with responses to only four 
peptides (Fig. 3.3, white box).  Positive peptide pools for each of the donors were 
deconvoluted to test the individual peptides and narrow down the peptide-specific 
response.  Table 3.3 summarizes all the peptides that elicited IFN-γ responses from the 
four donor PBMCs.  On average, the four donors’ PBMCs responded to 21 different 
peptides from nine different viral proteins, including H3 and H5 HA. Responses to H3 
and H5 HA were comparable, with SFC values ranging from 20 to 60 SFC per million 
cells. Most of these peptides do not contain a known epitope sequence based on our 
search using the Immune Epitope Database (IEDB; www.immuneepitope.org) (28, 155). 
We considered a peptide sequence to be a potential novel epitope if there was no record 
that the sequence was associated with positive T-cell data in the IEDB. We also 
considered both the amino acid sequence of the 17-mer peptide and the corresponding 
HLA allele of the donor’s PBMCs that responded.  Some of the peptides we identified 
have a record of some positive T-cell data in IEDB, but were not fully characterized with  
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Figure 3.3. Broad T-cell responses to influenza viral proteins in PBMC from healthy 
adults.  PBMCs from four healthy adults were screened for IFN-γ responses to all 
influenza proteins in ELISPOT assays.  Each bar corresponds to the total number of 
peptides that elicited an IFN-γ response in all donor PBMC tested. 
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regard to their HLA restriction or minimal epitopes (indicated in Table 3.3).  About 60% 
of these peptides gave “moderate” IFN-γ responses (SFC between 31 to 99 SFC/106) 
compared with the number of IFN-γ-producing cells responding to the 
“immunodominant” HLA-A2-restricted M158-66 epitope (Fig. 3.4).  
To determine if the IFN-γ responses we saw to the peptides were representative of 
the IFN-γ responses elicited during a viral infection, we took the sum of the SFC values 
to the peptides for each donor and compared it the SFC values during live virus 
stimulation.  Table 3.4 lists the sum of the number of IFN-γ-producing cells responding 
to these positive peptides for donors 2, 3, and 4, as well as the SFC values for live virus 
stimulation of these donors’ PBMCs.  By taking the sum of the responses after 
stimulation with the complete set of the peptides spanning all viral proteins, we find that 
our total SFC values for all the viral proteins are comparable with that of live virus 
stimulation in ELISPOT.  
 
D. The phenotype of IFN-γ producing cells 
To determine the T-cell population that produced IFN-γ after peptide stimulation, we 
depleted CD4+ or CD8+ cells from the donors’ PBMCs.  We then performed ELISPOT 
using the peptide of interest to stimulate the CD4+- or CD8+-depleted cells. Peptides that 
had SFC values greater than 60 SFC/106 in Table 3.3 were first analyzed to ensure that 
there are enough peptide-specific precursor cells. Except for the M158-66 epitope, all of 
the IFN-γ-producing cells that responded to the peptides in ELISPOT were CD4+ cells, as  
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Figure 3.4. Distribution of SFC values of positive peptides in ELISPOT assays. The 
SFC values for each peptide that gave a positive IFN-γ response were plotted in a 
histogram chart to determine the frequency of IFN-γ-producing cells among four donor 
PBMCs. 
 
 
 
 
 
 
 
 
 
 
72 
 
 
 
Table 3.4. Total SFC values corresponding to IFN-γ responses in ELISPOT to 
influenza peptide stimulation or live virus infection. 
 
 Total SFC valuesa 
H1 and 
hN1 
peptides 
H3 and N2 
peptides 
H5 and 
aN1 
peptides 
Internal 
protein 
peptides 
H1N1 
virus 
infection 
H3N2 
virus 
infection 
Donor 1 202 264 180 620 1221 1219 
Donor 2 0 52.5 0 52.5 NDb 420 
Donor 3 0 985 0 1825 1182 1478 
Donor 4 0 273 193 714 1033 1135 
 
aTotal SFC values are representative of one ELISPOT experiment, with triplicate wells 
per peptide or virus stimulation. 
 
bND, not done. 
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indicated by a drastic decrease in SFC values when CD4+cells are depleted from whole 
PBMCs (Table 3.5).  
For the other candidate peptide epitopes, short term bulk culture cell lines using donor 
PBMCs were set up and ICS was performed on days 12–14 to determine the phenotype 
of the IFN-γ-producing cells.  Fig. 3.4 illustrates representative plots indicating the 
phenotype of IFN-γ-producing cells from peptide-stimulated bulk culture using donor 3 
PBMCs. More than 87% of IFN-γ-producing T cells expressed the CD4 surface marker 
upon cognate peptide stimulation in ICS (Fig. 3.4).  
 
E. Characterization of the influenza-specific T cell lines generated from limiting 
dilution assay 
We generated bulk culture lines by stimulating donor PBMCs with peptides of 
interest to further characterize the peptide-specific responses we identified in our 
ELISPOT screening. We selected peptides that potentially contain novel epitopes by 
searching for MHC class I and class II binding motifs within the peptides using two 
prediction algorithms, HLA Peptide Binding Predictions (http://www-
bimas.cit.nih.gov/molbio/hla_bind/) (153) and SYFPEITHI (http://www.syfpeithi.de) 
(169).  We used these peptides to stimulate donor PBMC and generate short-term bulk 
culture cell lines.  After two weeks in culture, the peptide specificity of these cell lines 
was determined by using a standard 51Cr release assay by looking at their ability to kill 
autologous BLCL targets pulsed with the cognate peptide.  Although cytotoxicity may 
not be a major function of virus-specific CD4+ T cells, our group had previously 
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Table 3.5.  Phenotype of IFN-γ-producing cells after CD4+ or CD8+ cell depletion. 
Peptide SFC/106 
Whole PBMCs CD4-depleted 
PBMCs 
CD8-depleted 
PBMCs 
    
DONOR 1    
aM158-66 401.7±32.3 281.7±4 0±2.5 
bH3 HA322-334 8.3±0 6.7±2.1 25±5.5 
H3 HA273-289 46.7±1.2 8.3±2.1 65±1.2 
M1234-250 53.3±5.9 1.3±1.5 57.3±6.6 
N2176-192 34.7±3.2 0±0.6 68±4.7 
DONOR 3    
M191-107 90.7±2.1 0±0.6 164.2±2.1 
M197-113 124±10.4 27.5±4 152.5±18.3 
M1205-221 68±8.2 7.5±1 174.2±4 
M1210-226 97.3±9.3 7.5±2 235±5 
M1216-232 22.7±0.6 0.8±0.6 50±5 
N2176-192 44±2 0.8±1.2 135±5 
NP109-125 74.7±1.5 7.5±1 95±5 
NP115-131 30±3.5 0.8±1.2 45±9.2 
NP175-191 22±3.5 0.8±1.2 20±12 
NP187-203 37.3±2.9 2.5±1.7 42.5±5.7 
NP193-209 52±4 4.2±1.5 102.5±8.5 
H3 HA249-265 25±8.5 2.5±1.4 25±0 
 
aM158-66 is an HLA-A2-restricted immunodominant epitope.  It is used here as a control 
peptide for positive CD8 T-cell responses in HLA-A2 donors. 
 
bH3 HA322-334  is an HLA-DR1-restricted epitope.  It is used here as a control peptide for 
positive CD4 T-cell responses in HLA-DR1 donors. 
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Figure 3.5 Flow cytometry to determine the phenotypes of IFN-γ producing cells in 
Donor 3 PBMCs.  Peptide-stimulated short term bulk culture cells using donor 3 PBMC 
were used as effectors in an ICS.  The peptides illustrated here were used to initially 
stimulate whole PBMC and establish the bulk culture.  The final peptide concentration 
was 10 µg/ml in all experiments.   
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established both CD8+ and CD4+ T cell lines using a standard 51Cr release assay (58, 71, 
83, 101, 102, 141). Peptide-stimulated bulk culture lines that had a specific immune lysis 
of ≥15% in 51Cr-release assays (E:T ratios of 10, 30, and 90 were tested) were used in a 
limiting dilution assay to generate peptide-specific T-cell lines. We were able to generate 
T-cell lines that are specific to peptides H3 HA267-283, H3 HA350-366, M1205-221, and M191-
107, as well as to known T-cell epitopes contained in peptides H3 HA321-337 
(PRYVKQNTLKLAT, HA322-334) restricted by HLA-DR1 and M155-71 (GILGFVFTL, 
M158-66) restricted by HLA-A2. A 51Cr-release assay was performed to determine the 
ability of the T-cell lines to kill targets pulsed with decreasing doses of cognate peptide. 
T-cell lines specific to H3 HA267-283, H3 HA350-366 and M1205-221 were able to kill peptide-
pulsed targets at a peptide concentration of 10 μg/ml (≥15% specific lysis, Table 3.6).  
We also determined the surface expression of CD4 or CD8 of these T-cell lines by 
flow cytometry.  The T-cell lines that were specific to H3 HA267-283 (1-3E2), H3 HA350-366 
(2-10D8), and M1205-221 (3-1C9) were CD4+ (Table 3.6), whereas the M1-M155-71-specific 
T-cell line was CD8+, as expected (data not shown). We also performed IFN-γ ICS by 
pulsing autologous BLCLs with the cognate peptide and adding the appropriate T-cell 
line prior to Golgi plug application (Fig. 3.6).  T-cell lines were able to produce IFN-γ 
upon cognate peptide stimulation of autologous APCs, comparable with the virus-
infected control, although only a low percentage of the 2-10D8 T-cell line produced IFN-
γ after stimulation with either live influenza A virus or the peptide.  
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Figure 3.6.  Influenza specific T cell lines generated from limiting dilution assay 
are CD4+ and secrete IFN-γ.  T cell lines were stimulated by culturing them with 
either virus-infected or peptide-pulsed autologous BLCLs as APC for six hours after 
Golgiplug application.  (A) The CD3+ LDAlow CD14-CD19- gated population were 
analyzed for their CD4 and CD8 surface expression.  (B)  The CD4+ T cells were 
analyzed for their IFN- γ expression after peptide or virus stimulation. 
PMA:ionomycin was used as a positive control.  Virus-infected APCs used for the 1-
3E2 and 2-10D8 T cell lines were infected with A/Wisconsin/67/2005X-161B 
(H3N2) virus, while APCs used for the 3-1C9 T cell line were infected with A/New 
Caledonia/20/1999 IVR-66 (H1N1) virus.   
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F. H1 HA and H3 HA T cell responses in 30 additional donors 
The human T-cell responses to influenza hemagglutinin are not well-characterized.  
Since we detected several HA-specific T-cell responses in the first four donors, we 
decided to analyze HA-specific T-cell responses using the PBMCs of 30 hospital 
workers.  These donor PBMCs were collected as part of a clinical study performed by our 
group (40).  Using the same ELISPOT strategy we previously employed, Laura Orphin in 
our laboratory screened pre-vaccination PBMCs from these donors to determine their 
baseline HA-specific T cell responses.  We did not include the H5 HA peptides from BEI 
because of the limited number of PBMCs.    Fifteen out of the 30 donors have memory 
responses to at least one HA peptide.  All fifteen responders had memory responses 
specific to the H3 HA, while five of them responded to H1 HA.   These results are 
consistent with our initial screening using four donor PBMCs where majority of the HA 
responses that we detected are to the H3 HA.   
 
 
 
 
 
 
 
80 
 
 
 
Table 3.7. Summary of H1 and H3 HA peptides that gave a positive IFN-γ response 
in our ELISPOT screening using PBMC from additional 30 donors.  
 
Protein 
AA 
Position 
Sequencea No. of Positive 
Donors 
SFC/106b 
H3 HA 13-29 LVFAQKLPGNDNSTATL 1 62.5 
H3 HA 37-53 PNGTIVKTITNDGIEVT 2 50, 107.5 
H3 HA 43-59 KTITNDQIEVTNATELV 2 30, 37.5 
H3 HA 59-75 VQSSSTGGICDSPHQIL 1 57.5 
H3 HA 83-99 IDALLGDPQCDGFQNKK 1 52.5 
H3 HA 107-123 SKAYSNCYPYDVPDYAS 2 40, 50 
H3 HA 119-135 PDYASLRSLVASSGTLE 1 22.5 
H3 HA 131-147 SGTLEFNNESFNWTGVT 1 37.5 
H3 HA 155-171 CKRRSNNSFFSRLNWLT 1 20 
H3 HAc 209-225 SLYAQASGRITVSTKRS 4 20, 25, 330, 167.5 
H3 HAc 215-231 SGRITVSTKRSQQTVIP 2 37.5 
H3 HAc 243-259 PSRISIYWTIVKPGDIL 5 33.3, 37.5, 40, 42.5, 75 
H3 HAc 249-265 YWTIVKPGDILLINSTG 4 27.5, 27.5, 32.5, 32.5 
H3 HAc 255-271 PGDILLINSTGNLIAPR 4 30, 22.5, 35, 50 
H3 HA 267-283 LIAPRGYFKIRSGKSSI 1 20 
H3 HA 291-307 GKCNSECITPNGSIPND 1 22.5 
H3 HA 321-337 CPRYVKQNTLKLATGMR 3 50, 35, 67.5 
H3 HA 344-360 TRGIFGAIAGFIENGWE 1 50 
H3 HA 368-384 GFRHQNSEGIGQAADLK 1 27.5 
H3 HA 386-402 TQAAINQINGKLNRLIG 2 27.5, 32.5 
H3 HA 397-413 LNRLIGKTNEKFHQIEK 1 22.5 
H3 HA 403-419 KTNEKFHQIEKEFSEVE 1 57.5 
H3 HA 409-425 HQIEKEFSEVEGRIQDL 1 57.5 
H3 HA 421-437 RIQDLEKYVEDTKIDLW 1 90 
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Protein AA 
Position 
Sequencea No. of Positive 
Donors 
SFC/106b 
H3 HA 433-449 KIDLWSYNAELLVALEN 3 35, 27.5, 57.5 
H3 HA 439-455 YNAELLVALENQHTIDL 2 22.5, 35 
H3 HA 457-473 DSEMNKLFERTKKQLRE 1 55 
H3 HA 463-479 LFERTKKQLRENAEDMG 1 20 
H3 HA 481-497 GCFKIYHKCDNACIGSI 3 62.5, 22.5, 80 
H3 HA 505-521 DVYRDEALNNRFQIKGV 1 85 
H3 HA 528-543 KDWILWISFAISCFLL 1 50 
H3 HA 550-566 FIMWACQKGNIRCNICI 1 47.5 
H1 HA 37-53 LEKNVTVTHSVNLLEDS 1 27.5 
H1 HA 156-172 GKSSFYRNLLWLTGKNG 1 35 
H1 HA 262-278 GNLIAPWYAFALSRGFG 1 60 
H1 HA 416-432 LERRMENLNKKVDDGFL 1 40 
H1 HA 434-450 IWTYNAELLVLLENERT 1 25 
H1 HA 458-474 VKNLYEKVKSQLKNNAK 1 37.5 
H1 HA 464-479 KVKSQLKNNAKEIGNG 2 65, 75 
H1 HA 480-496 CFEFYHKCNNECMESVK 1 45 
H1 HA 510-526 KLNREKIDGVKLESMGV 1 35 
H1 HA 527-543 YQILAIYSTVASSLVLL 1 20 
H1 HA 545-560 SLGAISFWMCSNGSLQ 1 42.5 
H1 HA 550-565 SFWMCSNGSLQCRICI 1 20 
a Underlined sequences are known influenza HA epitopes.  Amino acids highlighted in 
yellow reflect an amino acid change in our peptide sequence compared to the previously 
published epitope.   
b SFC values are representative of one ELISPOT experiment with three replicate wells. 
c This peptide contains amino acid residues that overlaps with another peptide and tested 
positive for IFN-γ response using PBMC from the same donor.  
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G. Influenza B HA screening  
The IBV is a component of the trivalent vaccine given annually, and IBV co-
circulates with IAV during most influenza seasons.  The T cell responses to IBV are also 
not well-characterized.  We thought of extending our ELISPOT screening using B HA 
peptides because we were able to detect several responses to the IAV HA proteins than 
previously reported.  Therefore, we performed a similar screening using peptides 
comprising the IBV pre-HA protein.  PBMCs from six additional healthy donors with no 
prior respiratory or influenza-like illness at the time of blood drawing were tested against 
pools containing 9 or 10 B/HA peptides at a final peptide concentration of 2 µg/ml.  All 
donors had detectable IFN-γ responses to at least one IBV HA pool (Fig. 3.8).  Our 
results indicate that there is a robust memory T cell population specific to the IBV HA 
protein that is generated from exposure to IBV through either natural infection or 
vaccination. 
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Figure 3.7.  T cell responses to the influenza B HA peptide pools.  Donor PBMCs 
were screened against peptide pools spanning the entire IBV B/HA.  Each legend 
represents an individual donor.  PHA stimulation is used as a positive control and is ≥ 
2000 SFC/106 for all donor PBMC.  Error bars represent the standard deviation in 
triplicate wells. (n = 6 donors). 
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H. Chapter Summary 
 
We performed a comprehensive screening of peptides covering all influenza A virus 
proteins to determine the breadth and depth of the T cell response to influenza at baseline 
levels.  Our results confirm previous reports that the T cell response to influenza is 
broadly directed to several viral proteins. We found that the surface glycoproteins, HA 
and NA, which are major components of inactivated vaccines, had many T cell epitopes.  
Majority of the responses that we detected were CD4+ T cell responses, probably due to 
the bias given by the length of the peptides that we used.  In addition, we found several 
CD4+ T cell epitopes in the HA protein and confirmed the abundance of this HA-specific 
T cell response by screening an additional 30 donors.  Healthy adults also have a robust 
memory T cell response to the IBV HA.  Genome-wide screening using overlapping 
peptides covering all viral proteins is useful in identifying T cell epitopes and is 
complementary to the approach based on predicted binding peptides to well-studied HLA 
alleles.   
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CHAPTER IV 
CHARACTERIZATION OF A CROSS-REACTIVE CD4 T CELL RESPONSE TO 
INFLUENZA A AND B HEMAGGLUTININS 
 
 We hypothesized that prior exposure to an IAV subtype generates memory T cells 
that can potentially contribute to HSI to a subsequent IAV of a different subtype.  Our 
group (102) and others (50, 180) previously identified H5 HA T cell responses in healthy 
individuals.   These individuals were not exposed to avian influenza, thus this T cell 
response to H5 HA must be cross-reactive.  Among the different HA subtypes, H2 and 
H5 HA are the closest based on their phylogeny (67). Because H2N2 only circulated 
from 1957-1968, this provided an opportunity to address the hypothesis that prior 
immunity to H2 HA may contribute to this cross-reactive T cell response.     
 
A. Screening of H2 HA and comparisons between older and younger donors 
Individuals who were previously exposed to the H2N2 virus would have a memory 
pool of H2 HA specific T cell responses.  Therefore, we sought to see if there are 
differences in the H2 HA responses in individuals born before the 1957 pandemic and 
those who were born after 1968, when H2N2 was last detected in the human population.   
IFN-γ ELISPOT assays were done to quantify the H2 HA memory T cells using H2 HA 
peptide pools to be able to compare the responses between older (born before 1957) and 
younger donors (born after 1968). We expected to detect responses to H2 HA in the 
PBMC of the older group but not in the younger donors. Indeed, seven of the 11 older 
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individuals’ T cells had IFN-γ responses to at least one peptide pool (Fig. 4.1A), although 
for most donors, the SFC values are modestly above our cut-off for a positive IFN-γ 
response (20 SFC/106) as described in Chapter III.  In our screening of T cell responses to 
the H2 HA peptides, we did not expect younger donors to have IFN-γ responses to the H2 
HA peptides.  However, four out of seven younger donors responded to a particular H2 
HA peptide pool.  Donors YD01 and YD04 had responses to peptides in the H2 HA 
peptide pool 7, while donors YD02 and YD06, had responses to peptides in the H2 HA 
peptide pool 9 (Figure 4.1B).  These younger donors were born well after 1968, when 
H2N2 was last detected in the human population. When we tested the individual peptides 
in these pools, the PBMC of donors YD02 and YD06 both had IFN-γ responses to H2 
HA339-355 (Fig. 4.2A), while YD04 had responses to H2 HA387-403 (Fig. 4.2B).  Based on 
these results, we hypothesize that the IFN-γ responses we saw in the PBMC of these 
donors may be due to cross-reactive memory T cells generated by exposure to more 
recently circulating seasonal influenza strains of the H1N1 and H3N2 subtypes.   
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Figure 4.1. IFN-γ responses of various donor PBMCs to H2 HA peptide pools.  (A) 
Older (n=11) and (B) younger donor PBMCs (n=7) were tested in ELISPOT against H2 
HA peptide pools to quantify and compare the IFN-γ responses to H2 HA.  Each peptide 
pool contains 9-10 non-overlapping peptides spanning the H2 HA and each point 
represents an individual donor.  Due to limited PBMCs collected from each donor, the 
ELISPOT peptide pool screening was only done once. Error bars represent the standard 
deviation in triplicate wells.  SFC values for the positive control, PHA, were between 
1245 -3664 SFC/106.  
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Figure 4.2. Deconvolution of positive H2 HA peptide pools.  (A) YD02 and YD06 
PBMC were screened against the individual peptides in H2 HA Pool 9, while (B) YD04 
PBMC was screened against the individual peptides in H2 HA Pool 7.  Error bars 
represent the standard error of the mean of triplicate wells.   
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B. The IFN-γ response to the H2 HA339-355 peptide is well-conserved in other HA 
subtypes and is mediated by CD4+ cells 
To determine if the H2 HA response we saw in YD02 and YD 06 was due to a 
cross-reactive memory T cell response to H1 and/or H3 HA, we tested the corresponding 
peptides in the H1 and H3 HAs.  We also included the corresponding peptides in H5 HA 
to see if this T cell response is also cross-reactive to H5.    Our ELISPOT screenings 
show that the donors’ T cells responded to these peptides (Fig 4.3A), especially to the 
peptides that contained the RGLFGAIAGF amino acid sequence (see Table 4.1 for 
sequence of HA peptides).   This sequence maps to the N-terminus of the HA2 subunit, 
which spans the fusion peptide of the influenza HA (48).   
The CD4+ or CD8+ expressing cells from YD02 PBMC were depleted by using 
MACS to identify the cell population that is responding to the peptides. We were only 
able to perform the experiment with donor YD02 PBMC because we had limited PBMC 
from YD06.  IFN-γ was produced in the presence of CD4+ cells in the PBMC, but not 
with CD8+ cells (Figure 4.3B).  The SFC values are also relatively increased when CD8+ 
cells are depleted due to enrichment of CD4+ cells, indicating that the peptides are 
presented by the MHC Class II molecule.    
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Figure 4.3. IFN-γ responses to corresponding peptide sequences in other A/HAs. (A) 
YD02 and YD06 PBMCs were screened against the corresponding 17-mer peptides in 
H1, H3 and H5 HAs that include a part or the entire RGLFGAIAGF amino acid sequence 
in ELISPOT.  Data is representative of two independent ELISPOT experiments. (B) 
YD02 PBMCs were depleted with either CD4 or CD8 expressing cells by negative 
selection using magnetic beads and were used in ELISPOT to determine the phenotype of 
IFN-γ responding cells. SFC values shown are adjusted for background spots given by 
the negative control SFC (2-3 SFC/106).  SFC values for the positive control, PHA, were 
greater than 2,000 SFC/106 in all experiments.  
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C. Characterization of in vitro generated cell line specific to H2 HA339-355  
To further characterize the T cell response to H2 HA339-355, we generated bulk 
culture lines by stimulating PBMC from YD02 with the peptide.  A limiting dilution 
assay at one, three or 10 cells per well in a 96-well plate was then set up to  isolate  T cell 
line(s) specific to H2 HA339-355.  We used a standard 51Cr release assay to select for 
peptide specific T cell lines from the limiting dilution plates as described in Chapter III.  
Selected T-cell lines that showed peptide specificity in our initial experiments were 
propagated and restimulated.  We found one T cell line that was able to kill autologous 
target BLCLs pulsed with H2 HA339-355 in a dose-dependent fashion (Figure 4.4A).  When 
we performed surface staining, greater than 97% of the live, CD3+cells were CD4+ 
(Figure 4.5).  A bulk culture line was also set-up by using YD04 PBMC and the H2-
HA387-403 peptide for stimulation, but we were not able to generate a specific T cell line 
after limiting dilution assay.   
The CD4+ T cell line was tested against target cells pulsed with corresponding 
peptides in H1, H3 and H5 HAs (Figure 4.4B).  As expected, this H2 HA339-355-specific T 
cell line was able to lyse those peptide-pulsed target cells.  The pattern of lysis is also 
consistent with the IFN-γ responses to the peptides in ELISPOT shown in Figure 4.3A 
(summarized in Table 4.1).  We also tested the H2 HA339-355 T cell line against target 
cells pulsed with various recombinant HA proteins in a 51Cr release assay (Fig. 4.6).  The 
T cell line recognized both recombinant HA from human influenza strains (H1, H2 and 
H3) and avian influenza HAs (H5 and H7).   
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Figure 4.4. Characterization of the H2 HA339-355-specific T cell line using a standard 
51Cr release assay. (A)  A dose response of the T cell line to H2 HA339-355 peptide was 
done using a standard 51Cr release assay. (B) The T cell line was also used as effector 
cells against autologous BLCLs pulsed with the corresponding peptides in other A/HAs. 
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Figure 4.5.  The H2 HA339-355 T cell line is a CD4+ T cell line.  In this surface staining, 
cells were first gated for singlets (FSC-H vs. FSC-A) and lymphocytes (SSC-A vs. FSC-
A).  The lymphocyte gate is further analyzed for their uptake of the Live/Dead Aqua stain 
to determine live versus dead cells and their expression of CD3 and CD19, taking only 
the live, healthy T cell population (LDA-/low, CD3+, CD19-).  CD4 surface expression is 
then determined from this gated population. 
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Figure 4.6. Ability of the H2 HA339-355-specific T cell line to recognize recombinant 
HA protein. Autologous BLCLs were treated with recombinant HA protein at a final 
concentration of 10μg/ml and used as targets in a standard 51Cr release assay using the H2 
HA339- 355-specific T cell line as effector cells. The recombinant H2 HA protein was 
tested in a separate experiment (light gray bars). The H2 HA339-355 was used as a positive 
control. 
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D. The H2 HA339-355 T cell line recognize autologous target cells infected with 
various influenza A viruses 
To determine if the T cell line can kill virus-infected targets, we infected 
autologous BLCLs with seasonal H1N1 and H3N2 strains, including a 2009 pandemic 
H1N1 strain.  Target cells were also infected with a reassortant H2N1 strain.  All of the 
virus-infected target cells were lysed specifically by the H2 HA339-355 T cell line (Fig. 
4.7A).   In a separate experiment, the avian H5N1 infected target cells were also lysed by 
the H2 HA339-355 T cell line (Fig. 4.7 A, gray bars).  This indicates that this peptide 
epitope was processed and presented by APCs during infection in vitro. 
 
E. The H2 HA339-355 T cell line can also recognize target cells infected with influenza 
B virus 
The fusion peptide sequence is well-conserved in the influenza HA, including the 
B/HA (48).  Therefore, we asked if this T cell line is able to recognize this sequence in 
the influenza B/HA as well.  Indeed, the T cell line killed both peptide-pulsed or B virus 
infected targets (Fig. 4.7B), indicating that this CD4+ T cell epitope is also presented in 
the context of an influenza B virus infection. 
 
 
97 
 
 
 
 
Figure 4.7.  Recognition of influenza virus infected target cells by the H2 HA339-355 T 
cell line.  (A) Autologous BLCLs were infected with several strains of IAV representing 
relevant IAV subtypes and were used as target cells in a 51Cr release assay.  (B) 
Responses to the corresponding B/HA peptides and B virus infection were also 
determined in a 51Cr release assay.  H2 HA339-355-pusled target cells were used as a 
positive control. 
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F. The H2 HA339-355 T cell line produces IFN-γ and TNF-α 
Influenza-specific CD4+ T cells have been shown to produce a variety of 
cytokines, including IFN-γ and TNF-α (136).  We performed an intracellular cytokine 
staining assay to identify the cytokines produced by the H2 HA339-355 T cell line upon 
stimulation with either peptide-pulsed or virus-infected target cells. The live CD3+CD4+ 
T cells (>95%) produced both IFN-γ and TNF-α when they are stimulated with 
autologous BLCLs that are pulsed with the fusion peptide epitope, but not with the 
negative control HLA-A2 restricted M158-66 epitope peptide (Fig. 4.8A).  We also 
infected autologous BLCLs with seasonal and pandemic H1N1 and H3N2 strains, a 
reassortant H2N1, and influenza B strain and used them to stimulate the H2 HA339-355 T 
cell line.  As with peptide stimulation, the CD4+ T cells were double-positive for IFN-γ 
and TNF-α with more than 50% of the cells producing both cytokines in response to viral 
infection (Figure 4.8B).    This response is specific only to influenza, since the T cell line 
did not respond to peptide stimulation using a vaccinia B5R epitope or to vaccinia virus 
(MOI of 1) infected APCs in ICS (Fig. 4.8C). 
 
 
 
 
 
99 
 
 
 
Figure 4.8. Cytokine profile of the H2 HA339-355-specific T cell line upon stimulation 
with peptide-pulsed or virus-infected autologous BLCLs. The H2 HA339-355-specific T 
cell line was incubated with either (A) peptide-pulsed (10μg/ml) (B) influenza virus-
infected or (C) vaccinia B5R epitope-pulsed or vaccinia virus-infected BLCLs for 5-6 
hours in the presence of Golgi plug.  The T cells were then stained with surface marker 
and intracellular cytokine fluorophore-conjugated antibodies to determine the cytokine 
profile after stimulation.  These plots were gated for live, CD3+, CD19-, CD4+ cells.  The 
cytokine response to peptide shown in (A) is representative of one out of three 
experiments.  Responses to viral infected targets, including vaccinia virus infection, were 
determined in a single experiment. 
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G. Determining the HLA restriction of the H2 HA339-355 –specific T cell epitope 
To determine the HLA-restriction of the T cell line, we first tested it against 
mismatched BLCLs, initially focusing on HLA-DR alleles.  The two donors who 
responded in our ELISPOT screening shared the HLA-DRB1*09 allele.  We performed a 
51Cr release assay using peptide-pulsed BLCLs expressing a variety of HLA class II 
alleles as target cells (Fig. 4.9A).  As expected, the T cell line was able to lyse the 
autologous targets cells expressing HLA-DRB1*03 and HLA-DRB1*09:01 even at a 
peptide concentration of 0.1µg/ml (Fig. 4.9A).  It also lysed target BLCLs that expressed 
the HLA-DRB1*09:01, although to a lesser extent compared to the autologous targets, 
but not BLCLs that have mismatched HLA-DR alleles.  Our results suggest that this 
epitope is restricted by HLA-DRB1*09.  We did not see comparable % specific immune 
lysis in both BLCLs that expressed the HLA-DRB1*09:01.  Aside from HLA-DR, there 
are two other MHC Class II molecules that are expressed and can present antigens in 
humans.  Therefore, to eliminate the possibility that this epitope is restricted by a 
different HLA Class II molecule, we pre-treated target autologous BLCLs with various 
concentrations of blocking antibodies to HLA-DR, HLA-DP or HLA-DQ and used them 
in a 51Cr release assay to further investigate the restriction of this T cell epitope.  The % 
specific immune lysis was reduced by more than 70% (from 37.82% to 9.54%) when 
target cells were treated with blocking antibodies to HLA-DR at a concentration of 5 
µg/ml, but not with anti-HLA-DQ or anti-HLA-DP (Fig. 4.9B), although the % reduction 
of specific immune lysis by the anti-HLA-DQ at a concentration of 0.625 µg/ml is close  
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Figure 4.9. Determining the HLA restriction of the H2 HA339-355 T cell epitope.   (A) 
The H2 HA339-355 T cell line was used effector cells against various mismatched BLCL 
targets in a 51Cr release assay.  A dose response to the H2 HA339-355 peptide was also 
determined.  The HLA-DRB1 alleles expressed by each BLCL are listed on the y-axis. 
(B) Target BLCLs were incubated with anti-HLA-DR, -DQ or -DP antibodies prior to the 
addition of peptide and effector cells in a 51Cr release assay.  The % reduction of lysis 
was determined by (%SILno Ab -%SILanti-HLA Ab)/(%SILno Ab) *100, where % SIL is the 
specific immune lysis value for that particular antibody treatment.  Data is representative 
of at least three separate experiments for each blocking antibody treatment. 
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to 60%.   This indicates that the restriction of this peptide epitope is not solely restricted 
by HLA-DR and that the donor’s particular HLA haplotype may contribute to 
promiscuity of this epitope.     
 
H. Ex vivo responses to the H2 HA339-355 epitope in donor PBMCs with the HLA-
DRB1*09 allele 
The two donors, YD02 and YD06, that responded to the H2 HA339-355 peptide in our 
initial ELISPOT experiments both express HLA-DRB1*09 allele.  We therefore tested 
additional donor PBMCs that have the HLA-DRB1*09 allele.  All of the five additional 
HLA-DRB1*09 expressing donors’ cells had ex vivo IFN-γ responses to the HA peptides 
containing the RGLFGAIAGF sequence of the fusion peptide (Table 4.3).   
An MHC Class II binding motif prediction algorithm 
(http://tools.immuneepitope.org/analyze/html/mhc_II_binding.html) from the IEDB (155) 
identified “IESRGLFGAIAGFIE” as a top 4.52% binder to the HLA-DRB1*09:01 
molecule as well as “ESRGLFGAIAGFIEG” (top 4.98%) and “SRGLFGAIAGFIEGG” 
(top 5.32%) among peptides in the HA protein of the A/Japan/305/1957 (H2N2) strain.  
We also ran a similar prediction query using the NetMHCIIpan-2.1 server 
(http://www.cbs.dtu.dk/services/NetMHCIIpan/), which ranks the predicted binding 
motifs against a set of 200,000 random natural peptides (145).  “IESRGLFGAIAGFIE”,  
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Table 4.2.  Healthy adult donors have ex-vivo IFN-γ responses to the fusion peptide 
epitope. 
 
Donor 
 
HLA Class II typing 
aSFC/106 
H1 H2 H3 H5 B/HA 
YD02 DRB1*03, 
DRB1*09:01:02 
22.7±1.73 26.7±2.65 46.7±2.65 32±5.86 14±1.53b 
YD06 DRB1*01, 
DRB1*09:01:02 
22.7±4.04 28±3.21 36±2.89 36±4.16 N.D. 
YD08 DRB1*04, DRB1*13 22.2±2.65 60±4.04b 66.7±2 22.2±3 7.4±2.31 
YD09 DRB1*09, DRB1*12 33.3±4 46.7±5.51 41.7±3.06 31.7±3.06 48.3±6.56 
YD10 DRB1*09, DRB1*14 101.7±4.24 96±10.50 84.7±11.79 71.2±7 81.4±9.17 
YD11 DRB1*01, DRB1*09 68±7.55 40±2.65 72±7 68±3.60 34.7±3.51 
YD12 DRB1*04:06, 
DRB1*09:01 
103.3±20.43 56.7±2.08 53.3±6.43 40±7 48.3±2.89 
YD13 DRB1*04, DRB1*09 N.D. 66.7±6.11 N.D. 30±3.46 N.D. 
 
a The SFC/106 values indicate the IFN-γ response of that donor to the HA peptide 
containing the conserved RGLFGAIAGF sequence.  The cut-off for a positive response is 
20 SFC/106. 
b Performed in a separate experiment. 
N.D. Not done. 
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“ESRGLFGAIAGFIEG”, and “SRGLFGAIAGFIEGG” are all in the top 16% of 
predicted binders to HLA-DRB1*09:01 (IC50 between 231-238 nM). Donor YD08 also 
had ex vivo responses to the H2 HA339-355 epitope, but did not have the HLA-DRB1*09 
allele (Table 4.3), suggesting the promiscuity of this epitope. 
 
I. Binding of the CD4+ T cell epitope containing the conserved fusion peptide 
sequence to  HLA-DR1 
We also performed a fluorescence polarization assay to determine the binding affinity 
of the H2 HA339-355 peptide to the HLA-DR molecule.  Since the HLA-DRB1*09 
molecule was not available for the assay we used HLA-DRB1*01:01 (HLA-DR1) 
molecule, which has a similar peptide binding motif in position 1 (55, 202) . We used 
overlapping H5 HA peptides containing parts of the fusion peptide sequence to determine 
the optimal 17-mer that can bind to HLA-DR1 (Fig. 4.10).  The H5 HA345-361 
(KRGLFGAIAGFIEGGWQ) had an IC50 of ~ 893 µM, which indicates that this 17-mer 
sequence can bind, although modestly compared to HA306-318, to HLA-DR1 (Table 4.3).  
This peptide sequence was also predicted to be a strong binder HLA-DRB1*01:01 (top 
16%; IC50 = 28.1 nM) using the NetMHCIIpan-2.1 server 
(http://www.cbs.dtu.dk/services/NetMHCIIpan/) (145) and belongs to the top 9.36% 
binders to HLA-DRB1*01:01 using the IEDB MHC Class II binding motif prediction 
algorithm      (http://tools.immuneepitope.org/analyze/html/mhc_II_binding.html) (155). 
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Figure 4.10. Binding of HA peptides to the HLA-DR1 molecule. Various 
concentrations of unlabeled HA peptides containing the fusion peptide sequence were 
mixed with Alexa-488-conjugated HA CD4 T cell epitope (HA306-318) to determine 
their binding affinity to recombinant soluble HLA-DR1. Unlabeled HA CD4 T cell 
epitope peptide was used as a positive control for binding to HLA-DR1. Values 
shown represent the mean of triplicate wells for a single experiment. 
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Table 4.3. IC50 values determined from Figure 4.10. 
Peptide aIC50 (nM) 
HA CD4 epitope (H3 HA306-318) 25.22±0.03 
H5339-355 24139±0.44 
H5345-361 893±0.09 
H5351-367 314640±0.39 
aIC50 values were determined by fitting to a competition  
binding equation using GraphPad Prism v5.04.  
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J. Chapter Summary 
We established a human CD4+ T cell line recognizing a cross-reactive epitope that is 
conserved among the different HA types of influenza A, and also the HA of influenza B. 
The epitope is located in the fusion peptide sequence of the influenza HA and contains 
the conserved RGLFGAIAGF sequence.  Our in vitro experiments show that the CD4+ T 
cell response to this epitope is characterized by the production of IFN-γ and TNF-α.  This 
epitope is recognized by individuals who have the HLA-DRB1*09 allele.  This epitope 
may also be promiscuous, as it was recognized by donor PBMC that did not have the 
HLA-DRB1*09 allele.  In addition, this epitope is able to bind the HLA-DR1 molecule in 
a biochemical assay.  To our knowledge, this is the first influenza CD4+ T-cell epitope in 
the HA protein that is cross-reactive to influenza A and B viruses.  The implications of a 
cross-reactive T cell response to HA are discussed in Chapter V. 
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CHAPTER V 
DISCUSSION 
 
A. The T cell response to influenza is broad and directed to several influenza 
proteins 
We performed a comprehensive screening of peptides covering all influenza A virus 
proteins. We confirmed previous reports by us (101) and others (10, 23, 76, 229) that the 
T-cell responses to influenza are broadly directed to multiple epitopes on several viral 
proteins. We found that surface glycoproteins, HA and NA, which are major components 
of inactivated vaccines, also had several T-cell epitopes. Overall, HA and M1 had more 
T-cell epitopes than other viral proteins, and those that we have done depletion 
experiments or by surface staining of peptide-stimulated bulk cultures with were of the 
CD4+ phenotype.  Recently, we (39) and others (89) reported that trivalent inactivated 
influenza vaccine can induce T-cell responses and that these T-cell responses may be 
targeting epitopes on HA, NA, and M1. Therefore, healthy adults have a broad and 
diverse memory T cell pool to influenza.  This is in agreement with the diversity of the T 
cell responses observed in human subjects to HIV(http://www.lanl.gov), CMV(213) and 
poxviruses (105, 148).   This memory T cell pool is generated by prior exposure to 
influenza by either natural infection and/or vaccination.   
There have been previous studies that looked at T-cell responses to all of the  
influenza proteins in humans, both by our group and others (76, 101), but they were 
limited by either focusing on well-conserved peptide sequences or by using the sequences 
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of the A/PR8, which was isolated more than 70 years ago and is not a circulating strain. 
Other groups that identify T cell responses to influenza focus on a particular influenza 
viral protein such as HA or M1 (50, 180, 243, 244), or determine influenza-specific T cell 
epitopes restricted to a particular HLA allele (242, 244).   The majority of the human T 
cell epitopes previously identified were to the internal proteins of influenza A.  This is 
most likely due to the conservancy of the amino acid sequence of these viral proteins 
among the different strains. Thus, previous efforts may have underestimated the breadth 
and depth of the T cell response to influenza.  In this thesis, we have employed a broader 
approach to genome-wide screening of T cell epitopes to influenza in humans (134) and 
this has been done by other groups as well (10).   
Although we have identified T cell responses to influenza that are directed to almost 
all of the viral components, there were limitations to the approach we used for epitope 
screening.  For several of the peptides that we identified, we were unable to determine 
whether T cells responding to a given peptide were CD4+ or CD8+ T cells.  Depletion of 
PBMCs with either CD4 or CD8 expressing cells prior to ELISPOT is a useful method to 
determine the T cell population responding to a particular peptide and we were able to do 
so for PBMC from Donor 1 and Donor 3.  However, this was limited by the amount of 
PBMCs we have collected from our donors.  In hindsight, depletion of PBMCs prior to 
screening of individual peptides from positive peptide pools determined by the initial 
ELISPOT experiments may have provided us more information as to the phenotype of 
the responding T cells.  We also did not use in vitro amplification of influenza A-specific 
T cells to avoid skewing the relative frequency of the T cells specific to each epitope. As 
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a result, the frequency of most peptide-specific T cells in PBMCs was not high enough to 
determine the phenotype by performing ICS experiments.  For the PBMC of Donor 3, we 
were able to determine the phenotype of responding T cells by stimulating the PBMC 
with peptide and maintaining short term bulk cultures that we used in ICS.  Again, we 
were limited by the PBMC that we have, since generating bulk cultures for each 
particular peptide would require a significant number of cells.   
Based on the ICS of Donor 1 PBMCs stimulated with live influenza A viruses 
(A/New Caledonia/20/1999 (H1N1) and A/Wisconsin/67/2005 (H3N2)), it is estimated 
that approximately 80% of T cells responding to a live virus infection are CD8+ T cells 
(data not shown).  This would indicate that majority of the T cell specificities present in 
response to a live virus infection are of the CD8+ phenotype.  However, all peptides for 
which we were able to perform further experiments with were recognized by CD4+ T 
cells, with the exception of the CD8+ T-cell epitope, M158-66. This could be explained by 
the length of peptides we used for the screening.  17-mer peptides may have stimulated 
CD4+ T cells better than CD8+ T cells, thus the sensitivity of detecting CD4+ T cells has 
been relatively higher. Ideally, we should have included influenza-naive donors as a 
negative control to demonstrate that T cells responding to influenza peptides have been 
generated against influenza virus exposure from either natural infection or vaccination. 
However, it is practically impossible to find influenza-naive adults (we cannot obtain 
large volumes of blood for genome-wide screening experiments from very young 
influenza-naive children). 
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Assarsson et al. recently reported that PB1 was the major target for both CD4+ 
and CD8+ T-cell responses (10). In our screening, we found that the HA (especially H3) 
and M1 were the major targets of T-cell responses. Our peptides were 17-mer 
overlapping by 11 amino acids covering all influenza A viral proteins. In their study, they 
used synthetic peptides based on the minimal epitopes predicted to have high-affinity 
binding to HLA class I or class II molecules and to be highly conserved based on 
prediction algorithms (10).  The use of minimal epitope peptides in the assays is likely to 
increase the sensitivity of detecting responding T cells, especially in the case of CD8+ T 
cells.  This is true in their study, where they were able to detect more CD8+ T cell 
epitopes compared to our results. The use of longer peptides covering all viral proteins is 
probably less sensitive in detecting specific CD8+ T cells, but it may detect T cells 
recognizing atypical T-cell epitopes or epitopes restricted by MHC class I or class II 
molecules whose binding motif predictions are not available (for example, HLA-DP and 
DQ alleles and rare HLA-A, -B, and -C alleles).  These differences in the peptide sets 
may explain why screenings by Assarsson et al. (10) and our study presented here 
produced different results. 
The HLA restriction of the epitope candidate peptides identified in this screening 
has not been experimentally determined, thus we were unable to test whether these 
epitopes could be identified by prediction algorithms.   However, in deciding which 
peptides to use in establishing peptide-specific T cell lines, we used prediction algorithms 
to determine binding motifs using the HLA alleles expressed by the donor PBMC that 
responded to a particular peptide as a determinant of MHC restriction. We think that our 
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results are complementary to those of Assarsson et al. (10) and that both approaches may 
be used, if possible, to identify T-cell epitopes on a virus. 
IFN-γ ELISPOT has been used to determine T cell responses to influenza and 
other viral pathogens including vaccinia virus (148), HIV (208) and  herpes simplex virus 
(HSV)-2 (162).  Although IFN-γ production represents majority of the T cell response to 
a particular pathogen, other cytokines may also characterize the T cell response.  One of 
the CD4+ T cell lines that we generated from a limiting dilution assay using cytotoxicity 
as a readout, 2-10D8, produced very minimal IFN-γ after stimulation with autologous 
BLCL pulsed with the cognate peptide or infected with influenza A virus (Chapter III, 
Fig. 3.6 B).  This cytotoxic CD4+ T cell line recognized a peptide epitope in HA that was 
initially identified in IFN-γ ELISPOT assays (Chapter III, Table 3.3; 25SFC/106).    We 
have not evaluated this T cell line for its ability to produce other cytokines.   This 
suggests that measurement of IFN-γ production alone may also underestimate the T cell 
response to influenza.   
Other cytokines can be used to evaluate the T cell responses to influenza in 
ELISPOT.  IL-2 is an important cytokine required for T cell proliferation and is produced 
by activated T cells.  In a screening of CD4 T cell epitopes to influenza using HLA-DR 
transgenic mice, IL-2 ELISPOT was used to determine the ex vivo T cell responses after 
intranasal influenza infection (172).  Another relevant cytokine to look at is IL-10, which 
has anti-inflammatory properties that may be able to mediate tissue damage and 
pathology in the course of influenza infection.  Both CD8+ and CD4+ effector T cells 
have been shown to simultaneously produce large amounts of IL-10 and IFN-γ during 
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acute influenza infection in mice (211).  In addition, virus-specific IL-10+ CD4+ memory 
T cells were readily detected 26 days post infection and were still detectable at day 9 
(35).  IL-10 producing human CD4+ T cells that are specific to the M1 protein and have 
T-regulatory characteristics have also been described recently (156).  Thus, a more 
thorough identification and characterization of the T cell response to influenza will have 
to assess the production of other cytokines in addition to IFN-γ, such as IL-2 and IL-10.   
 
B. The T cell responses to influenza A hemagglutinins 
In our genome-wide screening, HA and M1 proteins were the major targets of the 
T cell response to influenza.  We expected to see that majority of the T cell responses 
would be towards the internal proteins of influenza because they are highly conserved.  It 
was interesting to see that despite the propensity of the HA gene to mutate and thus, 
potentially generate escape mutations in T cell epitope sequences, a significant portion of 
the memory T cell responses were still directed to epitopes in the HA protein.  Because 
we only screened four individuals, we determined if we would see a similar robust HA 
response by screening more donors’ PBMC.  The abundance of T-cell responses against 
HA was confirmed by analyzing the PBMCs of 30 additional healthy donors by screening 
with HA peptides covering H1 and H3 HA in IFN-γ ELISPOT.  More responses to H3 
HA were seen than to H1 HA (53.3% of the donors responded to H3 and 16.7% to H1); 
thus, it is probably not surprising that we did not detect H1 HA-specific responses among 
the four healthy donors we previously screened. These may reflect (1) the epidemiology 
of currently circulating influenza A strains during the time when PBMC samples were 
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collected, (2) the history of prior infections with H3N2 versus H1N1 viruses in these 
individuals, or (3) higher virulence of H3N2 strain than H1N1 strain, all of which are 
factors that are difficult to ascertain.  A surveillance of influenza and pneumonia-related 
cases in the United States spanning fifteen years reveal that the H3N2 subtype has a 
higher severity index, causing more illness and increased mortality compared to the co-
circulating H1N1 or IBV (197), which is consistent with the third factor.    
The amino acid sequence identity between the HA and NA of A/New 
Caledonia/20/99 (H1N1) and A/Wisconsin/67/2005 (H3N2) is 40% for the HA 
(AAP34324 and ABW80978) and 42% for the NA (CAD57252 and ABP52004), 
respectively. This suggests a low probability of identifying subtype cross-reactive T-cell 
epitopes in these proteins. However, in two of the four healthy adult donors whose 
PBMCs were screened we detected T cells responding to the peptides encoded by the H5 
HA gene in IFN-γ ELISPOT assays.  Although the frequencies of these T cells were not 
high, they were comparable with those responding to the peptides encoded by the H3 HA 
gene. Other groups have also identified cross-reactive memory T-cell responses to avian 
H5N1 proteins in healthy individuals who were previously infected or exposed to 
seasonal influenza, as well as in individuals who received seasonal influenza vaccination 
(77, 79, 115, 128, 180), including our group (102). The donors included in these studies 
were unlikely to have been exposed to H5N1.  Most of the cross-reactive responses they 
identified were toward the internal proteins M1 and NP (115, 128), which is expected 
because the internal proteins are highly conserved, even among the different subtypes. 
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They were also able to identify cross-reactive responses to the HA (128, 180) and NA 
(77) proteins. 
Roti and colleagues (180) reported the presence of CD4+ T cells recognizing 
epitopes encoded by H5 HA gene in healthy individuals, who were unlikely to have been 
exposed to the H5N1 virus, although in vitro amplification of specific T cells was needed 
to detect them, suggesting a low frequency of these H5 HA cross-reactive T cells. These 
donors who had H5 HA-specific responses were old enough to have been exposed to 
H2N2 and H2 and H5 HA are the most related HA. However, they reported that none of 
the H5 HA epitopes identified was uniquely cross-reactive to H2 HA.  Their findings 
suggest that exposure to H2N2 viruses is not essential for cross-reactivity to H5 HA. 
Except for two peptides (H5151-167 and H5243-259 in Table 3.3) that have a four- to eight-
amino-acid overlap with the H5 HA epitopes identified by them, the H5 HA peptides that 
our donors’ PBMCs responded to are different.  We performed a multiple alignment 
between the H5 HA peptide we identified and the corresponding sequence in H1, H2 and 
H3 HAs (Fig. 5.1).  As expected, H2 and H5 HAs have more sequence similarity, and 
there was some level of homology with the H1 HA, but not with H3 HA in peptides that 
span the HA2 subunit of H5 HA (HA347-568, underlined in Fig. 5.1).  We also did not 
observe responses to the H1 and H3 HA peptides corresponding to the eight H5 HA 
peptides in these donors.  Therefore, we sought to detect H2 HA responses in donors who 
have been exposed to H2N2 and determine if these are cross-reactive to H5 HA.  We 
detected H2 HA-specific T cell responses in both older and younger donors, suggesting 
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Figure 5.1. Multiple alignment of cross-reactive H5 HA peptide epitopes and their 
corresponding sequence in H1, H2 and H3 HA.  Alignment was determined using the 
align sequences analysis tool of the Influenza Research Database 
(http://www.fludb.org/brc/analysis_landing.do?decorator=influenza). 
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that H2N2 exposure is not essential for H5 HA cross-reactivity, as previously proposed 
by Roti and colleagues (180).    
Many of the novel HA T cell epitopes we detected and those previously defined 
are located on conserved segments of the HA protein sequence, with the majority of them 
clustering at the C terminus. A previous study correlated the H3 three-dimensional 
structure and the epitopes that had been identified in mice and humans and found that the 
dominant epitopes to HA are primarily located in conformationally stable segments of the 
C-terminal region (126). In addition, a recent study using HLA-DR1 transgenic mice 
identified a diverse HA-specific, HLA-DR1- restricted CD4+ T cell response, with the 
majority of epitopes located in conserved HA regions (172).  Although we were not able 
to determine the MHC restriction of the HA-specific T cell responses we identified in 
ELISPOT (except for those that responded to Donor 1 and 3, Chapter III), we suspect that 
they are of the CD4+ phenotype.  As mentioned above, our ELISPOT screening strategy 
lends an unintentional bias towards detecting CD4+ T cell responses due to the length of 
the peptides we used for screening.  
The CD4+ T cell epitope PKYVKQNTLKLAT, was one of the first human CD4+ 
T cell epitopes identified (122), and  initially was thought to be immunodominant (123, 
249).   It has been used in several studies to characterize and describe the CD4+ T cell 
responses to influenza (30, 52, 74, 129, 164, 189).  Subsequent studies have shown that a 
number of HA-derived CD4+ T cell epitopes can be recognized in infected individuals 
(75) and healthy adults (12, 180).  Several HA-specific CD4+ T cell epitopes have also 
been identified by using transgenic mice expressing HLA-DR1 (172) and HLA-DR4 
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(242).  A study that looked at the CD4+ T cell memory phase in influenza infection using 
HLA-DRI transgenic mice found that although the overall memory response to influenza 
remains diverse and directed to several influenza proteins, they saw a modest but 
reproducible shift towards HA-derived epitopes (173).  Our data and these studies 
suggest that a significant portion of the CD4+ T-cell responses to influenza are directed to 
the HA, and most of them are in regions that are structurally and functionally conserved. 
A possible explanation could be that repeated exposure to different virus strains through 
infection or immunization may selectively stimulate T cells specific to the epitopes 
located in conserved regions of HA.   
 
C. Cross-reactive CD4+ T cell epitope to Influenza A and B HA 
We established a human CD4+ T cell line recognizing a cross-reactive epitope that is 
conserved among the different HA types of influenza A, and also the HA of influenza B. 
The epitope is located in the fusion peptide sequence of the influenza HA.  We also found 
adult donors’ T cells had ex vivo IFN-γ responses to the peptides that contain the 
RGLFGAIAGF sequence (H2 HA340-349) of the fusion peptide by ELISPOT.  There were, 
however, notable differences in the T cell responses to the RGLFGAIAGF sequence-
containing peptides form different HAs.  It would seem that the flanking residue in either 
the N-terminus or C-terminus of the conserved RGLFGAIAGF sequence may influence 
how these peptides are recognized (Chapter IV, Table 4.1).  These differences can be 
attributed to the effect of flanking residues on the affinity of the peptide-MHC to the T 
cell receptor (42, 145).  The differences in the T cell responses to the HA peptides can 
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also be due to the peptide registry that is bound to the MHC pocket.  A detailed study 
binding motif of HLA-DRB1*0901 indicate that the binding of antigenic peptides 
depends on the interactions between pocket 6 and 9 (100).   We speculate that the 
different overlapping peptides containing the conserved sequence may have different 
peptide registries, allowing for one peptide to bind more efficiently than the other.   
Analysis of evolutionarily conserved sequences in the different influenza A viral 
components reveal that the FGAIAGFIE sequence of the fusion peptide is the only region 
in the HA protein that is 98-100% conserved in influenza viral strains of the different 
human and avian influenza subtypes that circulated between 1997 to 2006 (91).  There is 
also significant conservation between the fusion peptide sequence of the HAs of IAV and 
IBV (118).   The fusion peptide plays a critical role in triggering fusion and destabilizing 
target membranes during the fusion process (48), thus there is strong functional restraint 
against mutation in this portion of the HA sequence.  A previous study using a mouse 
model showed that the stability of the fusion peptide sequence enhanced the 
immunogenicity of CD4 T cell epitopes adjacent to the fusion domain (168).  Our 
findings show that the fusion peptide itself contains a CD4+ T cell epitope as well.     
The CD4+ T cell epitope that we describe here is likely to be restricted by HLA-
DRB1*09, although it could possibly bind to other HLA-DR molecules as well, as 
previously shown for the HA306-320 CD4+ T cell epitope (249).  In fact we have shown 
that this CD4+ T cell epitope peptide can bind to the HLA-DR1 molecule in a 
biochemical assay (Fig. 4.10).  Moreover, all seven of the HLA-DRB1*09 donors’ 
PBMC have ex vivo IFN-γ responses to the fusion peptide epitope in ELISPOT.  The 
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ethnic origin of the HLA-DRB1*09 allele is Caucasoid and Oriental (www.ebi.ac.uk/cgi-
bin/imgt/hla/get allele.cgi?DRB1*09:01:02) and recent studies show that this allele is 
frequently present in East and Southeast Asian populations (152, 165, 178, 250), in 
particular the Han Chinese, which comprise more than 90% of the population of 
mainland China. In a high resolution genotyping of the HLA-DRB1 locus of individuals 
from Jiangsu Province, China, HLA-DRB1*09:01 is the most frequent allele (15.26%) 
(165).   It would be interesting to determine the contribution of this fusion peptide-
specific CD4+ T cell response to influenza immunity in this population. We also detected 
ex vivo T cell responses to the fusion peptide in one donor who is not HLA-DRB1*09.  In 
addition, our experiments using blocking antibodies to HLA-DQ (at 0.625 µg/ml) showed 
a reduction of specific lysis to some extent, thus we cannot rule out completely that the 
epitope is restricted by HLA-DP or –DQ.  The HLA Class II typing for donor YD02, 
from which the T cell line was derived from, is HLA-DRB1*0901, HLA-DRB1*03, 
HLA-DQB1*02, HLA-DPB1*05:01 and HLA-DPB1*28:01.  Using the T cell epitope 
prediction tool of IEDB, the 15-mer “RGLFGAIAGFIEGGW” is among the 11.21% top 
binders to the HLA-DQA1*05:01/DQB1*02:01 allele and is among the 18.17% top 
binders to the HLA-DRB1*03:01 allele.  This suggests that this peptide epitope could 
also be presented by HLA Class II molecules encoded by HLA-DP or DQ alleles.  We 
were not able to obtain the HLA-DQ and HLA-DP typing of the donor PBMC that we 
used to detect ex vivo responses to the fusion peptide.  It would be interesting to 
determine the contribution of the genotypic combination of HLA class II haplotypes to 
the fusion peptide-specific T cell response. 
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This CD4+ T cell epitope is also conserved in the HA of influenza B viruses.  
Influenza A and B viruses are almost the same in structure by electron microscopy, with 
both having the same number of gene segments that encode for the viral proteins (181).  
At the amino acid level, however, sequence similarities are only 12 to 37% for all 
proteins except for basic polymerase 1, which is 61% similar (Table 1.1; (98)). Influenza 
B has a larger genome, and its membrane channel protein is quite different from 
influenza A (181).  Although a number of CD4+ and CD8+ T cell epitopes in influenza A 
viruses have been identified using different strategies (IEDB, www.immuneepitope.org), 
only a few T cell epitopes have been identified in influenza B viruses.  An HLA-A*0201-
restricted CD8+ T cell epitope located in the NP (NP85-94) has been studied most 
extensively (175, 176, 195).  There are also two HLA-B8-restricted CD8+ T cell epitopes 
also located in the NP (NP30-38 and NP262-271) that have been identified (177) and one 
HLA-DRB1*0101-restricted CD4+ T cell epitope that is located in the HA (HA308-320) 
(177). These epitopes were identified by generating peptides from these two viral 
proteins based on prediction algorithms and using them to stimulate CTL responses in 
PBMC from a limited number of donors. Robust ex vivo responses to the IBV HA pools 
were detected in ELISPOT (Fig. 3.7) suggesting that B/HA-specific T cell responses are 
elicited through natural infection or vaccination.  Further studies to determine the role of 
these memory T cell responses should be done since IBV contributes to the burden of 
influenza disease (133, 150) and is a major component of the influenza vaccination that is 
currently being administered.  The identification of a cross-reactive T cell epitope that is 
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shared by both IAV and IBV provides an interesting avenue to explore how such a cross-
reactive T cell response may contribute protection to both influenza virus types. 
 
D. The relevance of cross-reactive CD4+ T cell responses in influenza infection 
A memory T cell pool is generated after initial encounter with influenza.  The 
presence of cross reactive T cells in the memory pool that can recognize a subsequent, 
but different, influenza subtype might be of an advantage.  They can proliferate more 
rapidly and are present at higher frequencies than antigen-specific naïve T cells allowing 
them to dominate the response to secondary (or tertiary) infection (234).  Our data 
suggest that a significant portion of the memory T cell response to influenza is comprised 
of CD4+ T cells, most of which are subtype cross-reactive.  The potential role of these 
cross-reactive T cells in HSI is summarized in Figure 5.2.   
CD4+ T cells may play an important role in HSI than previously appreciated.  
Immunization with either A/H1 N1 or A/H3N2 of β2-microglobulin -/- mice that lack 
MHC Class I expression and do not have CD8+ T cells, are protected against a 
heterosubtypic challenge as indicated by the viral titers in the lung and survival after 
challenge, but depletion of CD4+ T cells in these knockout mice partially abrogated this 
protection implying the contribution of CD4+ T cells to HSI (62).  Cross-reactive CD4+ T 
cells also play important roles in generating robust antibody responses to influenza (182) 
and adoptive transfer of CD4+ T cell clones specific to HA, NA, M1 or NP of A/PR8 in 
athymic mice one day after infection enhanced the anti-HA antibody response (183).   
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Figure 5.2. A simplified model of the role of cross-reactive CD4+ T cells in 
heterosubtypic immunity to influenza.  (A) After initial encounter of an IAV of a given 
subtype (I), effector CD4+ T cells that are both subtype specific (blue) and cross-reactive 
(yellow) are generated.  They act in concert with components of the innate and humoral 
arms of the immune response (not shown) to resolve the infection (gray background).  
During a second encounter with an IAV of a different subtype (II), subtype specific CD4+ 
T cells are generated at later stages of the infection (red), but memory CD4+ T cells that 
are subtype cross-reactive (yellow) can be readily expanded at earlier stages of infection, 
potentially contributing to partial protection to subtype II resulting to a less severe 
disease (gray background).    The immune mechanisms by which partial protection can 
occur are illustrated in B.  (B). Cross-reactive T cells generated from a previous 
encounter with subtype I can provide T cell help to antibodies and exhibit intrinsic 
effector functions upon encounter with subtype II.  Vaccination strategies that can 
stimulate these subtype cross-reactive T cells should be considered. 
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Thus, cross-reactive CD4+ T cells can contribute to protection by promoting the 
production of anti-HA antibodies. 
The question remains: if cross-reactive CD4+ T cells are restimulated every time we 
get exposed to influenza antigens, why are they not preferentially expanded and therefore 
dominate the response during a subsequent infection or repeated vaccination?  This is not 
an easy question to address, since the immune response to influenza is characterized by 
both humoral and cell-mediated responses, not to mention a potent innate immune 
response that can affect the outcome of the adaptive immune response.  A possible 
hypothesis is that the immunodominant responses directed to the conserved internal 
proteins and to CD8+ T cell epitopes may overwhelm the cross-reactive T responses 
directed to these CD4+ T cell targets, including the conserved HA epitope we describe 
here.    Because CD8+ T cells target internal proteins which are highly conserved, the 
presence of these conserved antigens during a subsequent infection may preferentially 
expand these cross-reactive CD8+ T cells.  The cross-reactive CD8+ T cell memory 
population could also be present at higher frequencies.  Both scenarios may allow certain 
immunodominant responses to dominate the memory response to influenza.  It is worth 
determining how we can boost these cross-reactive CD4+ T cell responses to these 
conserved regions in the HA and to study the mechanism by which they contribute to 
protection against influenza. 
 
 
125 
 
 
 
E. Implications to vaccine design 
The gold standard of influenza vaccination has always been the generation of 
neutralizing antibodies targeting HA.  However, with recent developments in the field, 
including our results, it seems that the most effective way to approach the design of a 
universal influenza vaccine is to be able to stimulate both humoral and cell-mediated 
arms of the immune response.  Several studies in other viral models of infection have 
shown that a broad-based T cell response that is directed against several epitopes seems 
to be appealing (24, 139).  With a broad-based cell-mediated immune response, the virus 
is less likely to accumulate mutations that may lead to immune evasion.  This is 
applicable in the case of influenza virus, since it accumulates several mutations through 
antigenic shift and drift.  It may also be relevant to consider vaccination strategies that 
will enhance cross-reactive CD4+ T cell responses since they have to potential be key 
effectors themselves while providing help to antibody producing B cells and CD8+ T 
cells.  The challenge remains to be the polymorphism of the HLA expression in humans, 
which causes the differential ability of various MHC molecules to present viral epitopes.  
One way to approach this is to take advantage of the presence of MHC supertypes. MHC 
class I or II molecules belonging to the same supertype can bind the same epitope peptide 
expanding the population coverage by the single epitope (55, 192, 194).  Given the 
different studies on human T cell epitopes to influenza compiled and curated by the 
IEDB, we can begin to look at the distribution of T cell epitopes restricted by a particular 
MHC supertype and determine ways in which we can stimulate these T cells in 
individuals with the MHC supertype. 
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The fusion peptide epitope that we have characterized here is cross-reactive to both 
IAV and IBV.  Although natural infection or standard vaccination may not induce strong 
T and B cell responses to this highly conserved epitope (21, 114), it is worth determining 
how we may be able to induce these cross-reactive CD4+ T cells by vaccination.  As with 
any vaccination strategy, careful evaluation of the role of these fusion peptide-specific, 
cross-reactive T cells in vivo is required.  The fusion peptide sequence is highly 
conserved in IAV and IBV but not influenza C and is also quite different from class I 
glycoproteins expressed by other viruses such as HIV and parainfluenza virus type 1 (48).  
However, a BLAST search of the first 12 amino acids (GLFGAIAGFIEG) of the 
influenza fusion peptide against known human protein sequences deposited in the NCBI 
database reveal that a few host proteins, mostly transport proteins (e.g. tricarobxylate 
transport protein, citrate transporter protein and solute carrier family 25), contain a 
similar sequence, “G-FGAIAG.”  This has important implications in inducing T cell 
responses to this peptide epitope as a vaccination strategy, since we do not want to induce 
a population of auto-reactive T cells.  There is evidence of viral epitopes that are cross-
reactive to self-antigens, such as a human CMV CD4+ T cell epitope that is recognized 
by  auto-reactive glutamic acid decarboxylase (GAD65)-specific T cells (94).  To our 
knowledge, there is no known auto-reactive epitope containing the fusion peptide 
sequence.  Further studies are needed to determine if the fusion peptide CD4+ T cell 
response that we describe here are potentially auto-reactive.   
We described a cross-reactive CD4+ T cell response specific to the fusion peptide of 
HA that is characterized by the production of pro-inflammatory cytokines IFN-γ and 
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TNF-α in vitro.  The ex vivo responses of healthy donors to the fusion peptide were also 
characterized by IFN-γ production.  There is also the possibility that instead of lending 
protective immunity, this cross-reactive T cell response may actually promote 
immunopathology instead, as seen in some models of heterologous immunity, wherein a 
T cell memory response to a particular virus is able to mediate the immune response to a 
subsequent infection by an unrelated virus (reviewed in (190, 234).  How this cross-
reactive response to the fusion peptide mediates protection remains to be determined, and 
could be challenging to ascertain in humans.   
Recent identification and characterization of several human cross-reactive 
monoclonal antibodies to epitopes located in the more conserved HA2 domain or the 
stalk region of HA have been reported (45, 57, 210, 238).  This has stimulated a novel 
approach of generating influenza virus vaccines based on the stalk region (including the 
fusion peptide) where a “headless” HA lacking the HA1 subunit is used as an immunogen 
that elicits immune sera with broader reactivity (205).  The presence of the cross-reactive 
CD4+ T cell epitope in the fusion peptide may be helpful to induce higher levels of cross-
reactive antibody responses, at least for individuals with the HLA-DRB1*09 allele (and 
other alleles with a similar peptide binding motif).  Several groups have also shown that 
these cross-reactive antibodies can be detected in human sera (44, 108, 221).  Specific 
activation of these helper T cells should be considered in designing or improving 
vaccination strategies to influenza. CD4+ T cell epitopes also tend to be more 
promiscuous than CD8+ T cell epitopes due to the nature of MHC class II molecules (84).  
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This may be advantageous when considering epitopes to be included in an improved 
vaccine for influenza since more than one HLA molecule can present the peptide. 
A peptide-conjugate vaccine based on the fusion peptide of the precursor HA of the B 
virus (using the outer membrane protein complex (OMPC) of Neisseria meningitides as 
conjugate) was shown to elicit protection in mice against lethal challenge of various 
strains of influenza B and can potentially be extended to influenza A strains (21).  
However, they also show naïve wild type mice that survived an IBV challenge do not 
have significant antibody titers to the fusion peptide suggesting that immunity to the 
cleavage site is not usually elicited during natural influenza virus infection (21).   A 
similar study using the fusion peptide conjugated to keyhole limpet hemocyanin (KLH) 
yielded similar results (203). Both studies did not evaluate the T cell response to the 
peptide-conjugate vaccine.  A more recent study examined the presence of HA2-specific 
antibodies in acute and convalescent sera from adults with confirmed H3N2 infection 
(204).  They found that a third (15/45) of the subjects had antibodies specific to the N-
terminal residues 1-38 of HA2, which includes the fusion peptide sequence.  They also 
confirm the previous report that the first few residues of HA2 are weak natural 
immunogens.  Nonetheless, it is interesting to note that a B cell epitope (11) and an HLA-
A2 restricted CD8+ T cell epitope (76)  have been previously described.  More recently, 
CD8+ T cells specific to the fusion peptide (H1 HA344-353) were detected at modest 
frequencies in vaccinated human subjects one year after vaccination (114).  These data 
indicate that the fusion peptide of the influenza HA is a relevant target of the immune 
response to influenza, which can be exploited to contribute to protective immunity.    
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F. Overall summary and conclusions 
In this thesis, we have shown that the human T cell immune response to influenza is 
broad and directed to several viral proteins, mostly to the HA and M1.  Although there 
were subtype specific T cell responses to the HA and NA, we identified several cross-
creative T cell epitopes not only to the more conserved internal proteins, but also to the 
more divergent HA protein.   We also saw T cell responses to the H5 HA in individuals 
who have not been previously exposed to H5N1 viruses.  These subtype-cross-reactive 
H5 HA responses were generated by prior exposure to seasonal influenza subtypes either 
by natural infection and/or vaccination and were not particularly attributed to T cell 
memory from H2 HA, contrary to our initial thought.  In addition, the subtype-cross-
reactive T cell responses to HA that we saw were directed to highly conserved regions. 
Among them, we identified and characterized an HA CD4+ T cell epitope that is highly 
conserved in both IAV and IBV HA.  This T cell epitope is probably restricted by the 
HLA-DRB1*09:01 allele, although it also can bind to HLA-DRB1*01:01 in a 
biochemical assay.   
Although we did not perform animal experiment to test whether the cross-reactive T 
cell responses that we identified here are able to contribute to HSI to influenza of a 
different subtype, existing literature on cross-reactive T cell responses to influenza as 
discussed above suggests that cross-reactive T cells can provide partial protection to a 
subsequent influenza infection.  Further characterization of these cross-reactive T cells in 
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the context of human influenza infection and vaccination and in consideration of the 
epidemiology of the virus is quite challenging, but is important in our understanding of 
the adaptive immune response to influenza.  Our knowledge of the T cell response to 
influenza, including the results we have described in this thesis, has implications for the 
improvement of current vaccination strategies and in the design of a universal influenza 
vaccine.   
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